Tel Aviv Department of Health, Ministry of how do i get kamagra Health, Tel Aviv, Israel, Ashkelon Academic College, School of go to the website Health Sciences, Ashkelon, Israel 3. Migrant Clinicians Network, Austin, TX, USA 4. International Organization for Migration, Geneva, Switzerland 5. Partasia Biopharm, New Delhi, India, SHARE INDIA, Delhi, India how do i get kamagra 6.
Paediatric Infectious Diseases and Vaccinology Unit, Mycobacterial and Migrant Health Research, University Children´s Hospital Basel, University of Basel, Basel, Switzerland 7. Centre for Global Public Health, Institute for Population Health Sciences, Queen Mary University of London, London, UKPublication date:01 May 2021More about this publication?. The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, how do i get kamagra including articles on TB, TB-HIV and respiratory diseases such as erectile dysfunction treatment, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print â simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.Editorial BoardInformation for AuthorsSubscribe to this TitleInternational Journal of Tuberculosis and Lung how do i get kamagra DiseasePublic Health ActionIngenta Connect is not responsible for the content or availability of external websitesDownload Article. Download (PDF 64.6 kb) No AbstractNo Reference information available - sign in for access.
No Supplementary Data.No Article MediaNo MetricsDocument Type. EditorialAffiliations:1. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 2. Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Westmead, NSW, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia 3.
Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australia, Faculty of Medicine and Health, School of Medicine, University of Sydney, Sydney, NSW, Australia, Children´s Hospital at Westmead,Westmead, NSW, AustraliaPublication date:01 May 2021More about this publication?.
Kamagra |
Avana |
Vidalista |
Tadalis sx |
Tentex royal |
|
Long term side effects |
22h |
2h |
19h |
22h |
19h |
How long does stay in your system |
In online pharmacy |
No |
Register first |
No |
Canadian pharmacy only |
Can women take |
100mg |
Consultation |
Consultation |
Consultation |
Ask your Doctor |
Where can you buy |
Yes |
No |
Yes |
No |
No |
Average age to take |
Yes |
Online |
No |
Yes |
Yes |
The proportion of transracial adoptionsâthose in which children are not of kamagra 100 effervescent the same race as either adoptive parentâalso increased, from 21 percent to http://magellandigitalmapping.ca/flagyl-online-without-prescription/ 28 percent of all adoptions. Despite this progress, hundreds of thousands of childrenâmore than 50 percent are children of colorâcurrently remain in foster care as they await permanent home placements. In June, the Trump administration issued an executive order that addressed the need to find permanent homes for all children waiting to be adopted.
In support, Mathematica partnered with kamagra 100 effervescent the Assistant Secretary for Planning and Evaluation (ASPE) to explore trends in adoption and attitudes about MEPA. Our research uncovered essential data about adoptions in the United States, including. Adoptions of Black children in 2017â2019 were 22 percent lower than in 2005â2007, whereas adoptions of White and Hispanic children increased by 41 percent and 36 percent, respectively, in the same time period.
The decline in adoptions of Black children was largely due to a declining number of kamagra 100 effervescent Black children in foster care over the time period (43 percent less). A childâs race is associated with the time spent in foster care before adoption. Black children adopted between 2017 and 2019 spent the longest time in foster care before adoptionâan average of 33 monthsâcompared to 27 months for White children and 28 months for Hispanic children.Raising awareness of these trends in adoption may help federal and state policymakers focus resources, technical support, and outreach strategies to states that need to improve their recruitment and retention of a diverse pool of adoptive and foster parents.
To learn more about this work, Mathematica and ASPE released several new research products. (1) a kamagra 100 effervescent detailed summary of the MEPA study. (2) a graphical fact sheet on trends in adoption and transracial adoption.
(3) an analysis of racial disproportionality in adoptive placements. (4) a report examining the attitudes about MEPA and race kamagra 100 effervescent issues in foster and adoptive placements in three states. And (5) a qualitative analysis of the content of states' plans for recruiting adoptive parents.As erectile dysfunction treatment disrupts peopleâs lives and livelihoods and threatens institutions around the world, the need for fast, data-driven solutions to combat the crisis is growing.
This primer is designed to help researchers, data scientists, and others who analyze health care claims or administrative data (herein referred to as âclaimsâ) quickly join the effort to better understand, track, and contain erectile dysfunction treatment. Readers can use this guidance to help them assess data on health care use and costs linked to erectile dysfunction treatment, create models for risk identification, and pinpoint complications that may follow a erectile dysfunction treatment diagnosis..
Since MEPA, how do i get kamagra adoptions have increased by 22 percent from 2005â2007 to 2017â2019 Flagyl online without prescription. The proportion of transracial adoptionsâthose in which children are not of the same race as either adoptive parentâalso increased, from 21 percent to 28 percent of all adoptions. Despite this progress, hundreds of thousands of childrenâmore than 50 percent are children of colorâcurrently remain in foster care as they await permanent home placements.
In June, the Trump administration issued an executive order that addressed the need to find permanent homes for all children waiting how do i get kamagra to be adopted. In support, Mathematica partnered with the Assistant Secretary for Planning and Evaluation (ASPE) to explore trends in adoption and attitudes about MEPA. Our research uncovered essential data about adoptions in the United States, including.
Adoptions of Black children in 2017â2019 were how do i get kamagra 22 percent lower than in 2005â2007, whereas adoptions of White and Hispanic children increased by 41 percent and 36 percent, respectively, in the same time period. The decline in adoptions of Black children was largely due to a declining number of Black children in foster care over the time period (43 percent less). A childâs race is associated with the time spent in foster care before adoption.
Black children adopted between 2017 and 2019 spent the longest time in foster care before adoptionâan average of 33 monthsâcompared to 27 months for White children and 28 months for Hispanic children.Raising awareness of these trends in adoption may help federal and state policymakers focus resources, technical support, and outreach strategies to states that need to improve their recruitment and retention of a diverse pool of adoptive and foster parents. To learn more about this work, Mathematica and ASPE released several new research how do i get kamagra products. (1) a detailed summary of the MEPA study.
(2) a graphical fact sheet on trends in adoption and transracial adoption. (3) an analysis of racial how do i get kamagra disproportionality in adoptive placements. (4) a report examining the attitudes about MEPA and race issues in foster and adoptive placements in three states.
And (5) a qualitative analysis of the content of states' plans for recruiting adoptive parents.As erectile dysfunction treatment disrupts peopleâs lives and livelihoods and threatens institutions around the world, the need for fast, data-driven solutions to combat the crisis is growing. This primer is designed to help researchers, data scientists, and others who analyze health care claims or administrative data (herein referred to as âclaimsâ) quickly join the effort to better understand, track, and contain erectile dysfunction treatment.
SILDENAFIL CITRATE is used to treat erection problems in men. Kamagra® is produced by Ajanta Pharma (India) in a GMP certified facility approved by Indian FDA.
Trial Population Table https://www.greenstealth.com/kamagra-online-paypal/ 1 kamagra reviews does work. Table 1. Characteristics of the Participants kamagra reviews does work in the mRNA-1273 Trial at Enrollment. The 45 enrolled participants received their first vaccination between March 16 and April 14, 2020 (Fig.
S1). Three participants did not receive the second vaccination, including one in the 25-μg group who had urticaria on both legs, with onset 5 days after the first vaccination, and two (one in the 25-μg group and one in the 250-μg group) who missed the second vaccination window owing to isolation for suspected erectile dysfunction treatment while the test results, ultimately negative, were pending. All continued to attend scheduled trial visits. The demographic characteristics of participants at enrollment are provided in Table 1.
treatment Safety No serious adverse events were noted, and no prespecified trial halting rules were met. As noted above, one participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient urticaria, judged to be related to the first vaccination. Figure 1. Figure 1.
Systemic and Local Adverse Events. The severity of solicited adverse events was graded as mild, moderate, or severe (see Table S1).After the first vaccination, solicited systemic adverse events were reported by 5 participants (33%) in the 25-μg group, 10 (67%) in the 100-μg group, and 8 (53%) in the 250-μg group. All were mild or moderate in severity (Figure 1 and Table S2). Solicited systemic adverse events were more common after the second vaccination and occurred in 7 of 13 participants (54%) in the 25-μg group, all 15 in the 100-μg group, and all 14 in the 250-μg group, with 3 of those participants (21%) reporting one or more severe events.
None of the participants had fever after the first vaccination. After the second vaccination, no participants in the 25-μg group, 6 (40%) in the 100-μg group, and 8 (57%) in the 250-μg group reported fever. One of the events (maximum temperature, 39.6°C) in the 250-μg group was graded severe. (Additional details regarding adverse events for that participant are provided in the Supplementary Appendix.) Local adverse events, when present, were nearly all mild or moderate, and pain at the injection site was common.
Across both vaccinations, solicited systemic and local adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Evaluation of safety clinical laboratory values of grade 2 or higher and unsolicited adverse events revealed no patterns of concern (Supplementary Appendix and Table S3). erectile dysfunction Binding Antibody Responses Table 2. Table 2.
Geometric Mean Humoral Immunogenicity Assay Responses to mRNA-1273 in Participants and in Convalescent Serum Specimens. Figure 2. Figure 2. erectile dysfunction Antibody and Neutralization Responses.
Shown are geometric mean reciprocal end-point enzyme-linked immunosorbent assay (ELISA) IgG titers to S-2P (Panel A) and receptor-binding domain (Panel B), PsVNA ID50 responses (Panel C), and live kamagra PRNT80 responses (Panel D). In Panel A and Panel B, boxes and horizontal bars denote interquartile range (IQR) and median area under the curve (AUC), respectively. Whisker endpoints are equal to the maximum and minimum values below or above the median ±1.5 times the IQR. The convalescent serum panel includes specimens from 41 participants.
Red dots indicate the 3 specimens that were also tested in the PRNT assay. The other 38 specimens were used to calculate summary statistics for the box plot in the convalescent serum panel. In Panel C, boxes and horizontal bars denote IQR and median ID50, respectively. Whisker end points are equal to the maximum and minimum values below or above the median ±1.5 times the IQR.
In the convalescent serum panel, red dots indicate the 3 specimens that were also tested in the PRNT assay. The other 38 specimens were used to calculate summary statistics for the box plot in the convalescent panel. In Panel D, boxes and horizontal bars denote IQR and median PRNT80, respectively. Whisker end points are equal to the maximum and minimum values below or above the median ±1.5 times the IQR.
The three convalescent serum specimens were also tested in ELISA and PsVNA assays. Because of the time-intensive nature of the PRNT assay, for this preliminary report, PRNT results were available only for the 25-μg and 100-μg dose groups.Binding antibody IgG geometric mean titers (GMTs) to S-2P increased rapidly after the first vaccination, with seroconversion in all participants by day 15 (Table 2 and Figure 2A). Dose-dependent responses to the first and second vaccinations were evident. Receptor-binding domainâspecific antibody responses were similar in pattern and magnitude (Figure 2B).
For both assays, the median magnitude of antibody responses after the first vaccination in the 100-μg and 250-μg dose groups was similar to the median magnitude in convalescent serum specimens, and in all dose groups the median magnitude after the second vaccination was in the upper quartile of values in the convalescent serum specimens. The S-2P ELISA GMTs at day 57 (299,751 [95% confidence interval {CI}, 206,071 to 436,020] in the 25-μg group, 782,719 [95% CI, 619,310 to 989,244] in the 100-μg group, and 1,192,154 [95% CI, 924,878 to 1,536,669] in the 250-μg group) exceeded that in the convalescent serum specimens (142,140 [95% CI, 81,543 to 247,768]). erectile dysfunction Neutralization Responses No participant had detectable PsVNA responses before vaccination. After the first vaccination, PsVNA responses were detected in less than half the participants, and a dose effect was seen (50% inhibitory dilution [ID50].
Figure 2C, Fig. S8, and Table 2. 80% inhibitory dilution [ID80]. Fig.
S2 and Table S6). However, after the second vaccination, PsVNA responses were identified in serum samples from all participants. The lowest responses were in the 25-μg dose group, with a geometric mean ID50 of 112.3 (95% CI, 71.2 to 177.1) at day 43. The higher responses in the 100-μg and 250-μg groups were similar in magnitude (geometric mean ID50, 343.8 [95% CI, 261.2 to 452.7] and 332.2 [95% CI, 266.3 to 414.5], respectively, at day 43).
These responses were similar to values in the upper half of the distribution of values for convalescent serum specimens. Before vaccination, no participant had detectable 80% live-kamagra neutralization at the highest serum concentration tested (1:8 dilution) in the PRNT assay. At day 43, wild-type kamagraâneutralizing activity capable of reducing erectile dysfunction infectivity by 80% or more (PRNT80) was detected in all participants, with geometric mean PRNT80 responses of 339.7 (95% CI, 184.0 to 627.1) in the 25-μg group and 654.3 (95% CI, 460.1 to 930.5) in the 100-μg group (Figure 2D). Neutralizing PRNT80 average responses were generally at or above the values of the three convalescent serum specimens tested in this assay.
Good agreement was noted within and between the values from binding assays for S-2P and receptor-binding domain and neutralizing activity measured by PsVNA and PRNT (Figs. S3 through S7), which provides orthogonal support for each assay in characterizing the humoral response induced by mRNA-1273. erectile dysfunction T-Cell Responses The 25-μg and 100-μg doses elicited CD4 T-cell responses (Figs. S9 and S10) that on stimulation by S-specific peptide pools were strongly biased toward expression of Th1 cytokines (tumor necrosis factor α >.
Interleukin 2 >. Interferon γ), with minimal type 2 helper T-cell (Th2) cytokine expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels after the second vaccination in the 100-μg dose group (Fig. S11).Patients Figure 1.
Figure 1. Enrollment and Randomization. Of the 1107 patients who were assessed for eligibility, 1063 underwent randomization. 541 were assigned to the remdesivir group and 522 to the placebo group (Figure 1).
Of those assigned to receive remdesivir, 531 patients (98.2%) received the treatment as assigned. Forty-nine patients had remdesivir treatment discontinued before day 10 because of an adverse event or a serious adverse event other than death (36 patients) or because the patient withdrew consent (13). Of those assigned to receive placebo, 518 patients (99.2%) received placebo as assigned. Fifty-three patients discontinued placebo before day 10 because of an adverse event or a serious adverse event other than death (36 patients), because the patient withdrew consent (15), or because the patient was found to be ineligible for trial enrollment (2).
As of April 28, 2020, a total of 391 patients in the remdesivir group and 340 in the placebo group had completed the trial through day 29, recovered, or died. Eight patients who received remdesivir and 9 who received placebo terminated their participation in the trial before day 29. There were 132 patients in the remdesivir group and 169 in the placebo group who had not recovered and had not completed the day 29 follow-up visit. The analysis population included 1059 patients for whom we have at least some postbaseline data available (538 in the remdesivir group and 521 in the placebo group).
Four of the 1063 patients were not included in the primary analysis because no postbaseline data were available at the time of the database freeze. Table 1. Table 1. Demographic and Clinical Characteristics at Baseline.
The mean age of patients was 58.9 years, and 64.3% were male (Table 1). On the basis of the evolving epidemiology of erectile dysfunction treatment during the trial, 79.8% of patients were enrolled at sites in North America, 15.3% in Europe, and 4.9% in Asia (Table S1). Overall, 53.2% of the patients were white, 20.6% were black, 12.6% were Asian, and 13.6% were designated as other or not reported. 249 (23.4%) were Hispanic or Latino.
Most patients had either one (27.0%) or two or more (52.1%) of the prespecified coexisting conditions at enrollment, most commonly hypertension (49.6%), obesity (37.0%), and type 2 diabetes mellitus (29.7%). The median number of days between symptom onset and randomization was 9 (interquartile range, 6 to 12). Nine hundred forty-three (88.7%) patients had severe disease at enrollment as defined in the Supplementary Appendix. 272 (25.6%) patients met category 7 criteria on the ordinal scale, 197 (18.5%) category 6, 421 (39.6%) category 5, and 127 (11.9%) category 4.
There were 46 (4.3%) patients who had missing ordinal scale data at enrollment. No substantial imbalances in baseline characteristics were observed between the remdesivir group and the placebo group. Primary Outcome Figure 2. Figure 2.
KaplanâMeier Estimates of Cumulative Recoveries. Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale (not receiving oxygen. Panel B), in those with a baseline score of 5 (receiving oxygen. Panel C), in those with a baseline score of 6 (receiving high-flow oxygen or noninvasive mechanical ventilation.
Panel D), and in those with a baseline score of 7 (receiving mechanical ventilation or ECMO. Panel E). Table 2. Table 2.
Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population. Figure 3. Figure 3. Time to Recovery According to Subgroup.
The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. Race and ethnic group were reported by the patients. Patients in the remdesivir group had a shorter time to recovery than patients in the placebo group (median, 11 days, as compared with 15 days. Rate ratio for recovery, 1.32.
95% confidence interval [CI], 1.12 to 1.55. P<0.001. 1059 patients (Figure 2 and Table 2). Among patients with a baseline ordinal score of 5 (421 patients), the rate ratio for recovery was 1.47 (95% CI, 1.17 to 1.84).
Among patients with a baseline score of 4 (127 patients) and those with a baseline score of 6 (197 patients), the rate ratio estimates for recovery were 1.38 (95% CI, 0.94 to 2.03) and 1.20 (95% CI, 0.79 to 1.81), respectively. For those receiving mechanical ventilation or ECMO at enrollment (baseline ordinal scores of 7. 272 patients), the rate ratio for recovery was 0.95 (95% CI, 0.64 to 1.42). A test of interaction of treatment with baseline score on the ordinal scale was not significant.
An analysis adjusting for baseline ordinal score as a stratification variable was conducted to evaluate the overall effect (of the percentage of patients in each ordinal score category at baseline) on the primary outcome. This adjusted analysis produced a similar treatment-effect estimate (rate ratio for recovery, 1.31. 95% CI, 1.12 to 1.54. 1017 patients).
Table S2 in the Supplementary Appendix shows results according to the baseline severity stratum of mild-to-moderate as compared with severe. Patients who underwent randomization during the first 10 days after the onset of symptoms had a rate ratio for recovery of 1.28 (95% CI, 1.05 to 1.57. 664 patients), whereas patients who underwent randomization more than 10 days after the onset of symptoms had a rate ratio for recovery of 1.38 (95% CI, 1.05 to 1.81. 380 patients) (Figure 3).
Key Secondary Outcome The odds of improvement in the ordinal scale score were higher in the remdesivir group, as determined by a proportional odds model at the day 15 visit, than in the placebo group (odds ratio for improvement, 1.50. 95% CI, 1.18 to 1.91. P=0.001. 844 patients) (Table 2 and Fig.
S5). Mortality was numerically lower in the remdesivir group than in the placebo group, but the difference was not significant (hazard ratio for death, 0.70. 95% CI, 0.47 to 1.04. 1059 patients).
The KaplanâMeier estimates of mortality by 14 days were 7.1% and 11.9% in the remdesivir and placebo groups, respectively (Table 2). The KaplanâMeier estimates of mortality by 28 days are not reported in this preliminary analysis, given the large number of patients that had yet to complete day 29 visits. An analysis with adjustment for baseline ordinal score as a stratification variable showed a hazard ratio for death of 0.74 (95% CI, 0.50 to 1.10). Safety Outcomes Serious adverse events occurred in 114 patients (21.1%) in the remdesivir group and 141 patients (27.0%) in the placebo group (Table S3).
4 events (2 in each group) were judged by site investigators to be related to remdesivir or placebo. There were 28 serious respiratory failure adverse events in the remdesivir group (5.2% of patients) and 42 in the placebo group (8.0% of patients). Acute respiratory failure, hypotension, viral pneumonia, and acute kidney injury were slightly more common among patients in the placebo group. No deaths were considered to be related to treatment assignment, as judged by the site investigators.
Grade 3 or 4 adverse events occurred in 156 patients (28.8%) in the remdesivir group and in 172 in the placebo group (33.0%) (Table S4). The most common adverse events in the remdesivir group were anemia or decreased hemoglobin (43 events [7.9%], as compared with 47 [9.0%] in the placebo group). Acute kidney injury, decreased estimated glomerular filtration rate or creatinine clearance, or increased blood creatinine (40 events [7.4%], as compared with 38 [7.3%]). Pyrexia (27 events [5.0%], as compared with 17 [3.3%]).
Hyperglycemia or increased blood glucose level (22 events [4.1%], as compared with 17 [3.3%]). And increased aminotransferase levels including alanine aminotransferase, aspartate aminotransferase, or both (22 events [4.1%], as compared with 31 [5.9%]). Otherwise, the incidence of adverse events was not found to be significantly different between the remdesivir group and the placebo group.Announced on May 15, Operation Warp Speed (OWS) â a partnership of the Department of Health and Human Services (HHS), the Department of Defense (DOD), and the private sector â aims to accelerate control of the erectile dysfunction treatment kamagra by advancing development, manufacturing, and distribution of treatments, therapeutics, and diagnostics. OWS is providing support to promising candidates and enabling the expeditious, parallel execution of the necessary steps toward approval or authorization of safe products by the Food and Drug Administration (FDA).The partnership grew out of an acknowledged need to fundamentally restructure the way the U.S.
Government typically supports product development and treatment distribution. The initiative was premised on setting a âstretch goalâ â one that initially seemed impossible but that is becoming increasingly achievable.The concept of an integrated structure for erectile dysfunction treatment countermeasure research and development across the U.S. Government was based on experience with Zika and the Zika Leadership Group led by the National Institutes of Health (NIH) and the assistant secretary for preparedness and response (ASPR). One of us (M.S.) serves as OWS chief advisor.
We are drawing on expertise from the NIH, ASPR, the Centers for Disease Control and Prevention (CDC), the Biomedical Advanced Research and Development Authority (BARDA), and the DOD, including the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and the Defense Advanced Research Projects Agency. OWS has engaged experts in all critical aspects of medical countermeasure research, development, manufacturing, and distribution to work in close coordination.The initiative set ambitious objectives. To deliver tens of millions of doses of a erectile dysfunction treatment â with demonstrated safety and efficacy, and approved or authorized by the FDA for use in the U.S. Population â beginning at the end of 2020 and to have as many as 300 million doses of such treatments available and deployed by mid-2021.
The pace and scope of such a treatment effort are unprecedented. The 2014 West African Ebola kamagra epidemic spurred rapid treatment development, but though preclinical data existed before the outbreak, a period of 12 months was required to progress from phase 1 first-in-human trials to phase 3 efficacy trials. OWS aims to compress this time frame even further. erectile dysfunction treatment development began in January, phase 1 clinical studies in March, and the first phase 3 trials in July.
Our objectives are based on advances in treatment platform technology, improved understanding of safe and efficacious treatment design, and similarities between the SARS-CoV-1 and erectile dysfunction disease mechanisms.OWSâs role is to enable, accelerate, harmonize, and advise the companies developing the selected treatments. The companies will execute the clinical or process development and manufacturing plans, while OWS leverages the full capacity of the U.S. Government to ensure that no technical, logistic, or financial hurdles hinder treatment development or deployment.OWS selected treatment candidates on the basis of four criteria. We required candidates to have robust preclinical data or early-stage clinical trial data supporting their potential for clinical safety and efficacy.
Candidates had to have the potential, with our acceleration support, to enter large phase 3 field efficacy trials this summer or fall (July to November 2020) and, assuming continued active transmission of the kamagra, to deliver efficacy outcomes by the end of 2020 or the first half of 2021. Candidates had to be based on treatment-platform technologies permitting fast and effective manufacturing, and their developers had to demonstrate the industrial process scalability, yields, and consistency necessary to reliably produce more than 100 million doses by mid-2021. Finally, candidates had to use one of four treatment-platform technologies that we believe are the most likely to yield a safe and effective treatment against erectile dysfunction treatment. The mRNA platform, the replication-defective live-vector platform, the recombinant-subunit-adjuvanted protein platform, or the attenuated replicating live-vector platform.OWSâs strategy relies on a few key principles.
First, we sought to build a diverse project portfolio that includes two treatment candidates based on each of the four platform technologies. Such diversification mitigates the risk of failure due to safety, efficacy, industrial manufacturability, or scheduling factors and may permit selection of the best treatment platform for each subpopulation at risk for contracting or transmitting erectile dysfunction treatment, including older adults, frontline and essential workers, young adults, and pediatric populations. In addition, advancing eight treatments in parallel will increase the chances of delivering 300 million doses in the first half of 2021.Second, we must accelerate treatment program development without compromising safety, efficacy, or product quality. Clinical development, process development, and manufacturing scale-up can be substantially accelerated by running all streams, fully resourced, in parallel.
Doing so requires taking on substantial financial risk, as compared with the conventional sequential development approach. OWS will maximize the size of phase 3 trials (30,000 to 50,000 participants each) and optimize trial-site location by consulting daily epidemiologic and disease-forecasting models to ensure the fastest path to an efficacy readout. Such large trials also increase the safety data set for each candidate treatment.With heavy up-front investment, companies can conduct clinical operations and site preparation for these phase 3 efficacy trials even as they file their Investigational New Drug application (IND) for their phase 1 studies, thereby ensuring immediate initiation of phase 3 when they get a green light from the FDA. To permit appropriate comparisons among the treatment candidates and to optimize treatment utilization after approval by the FDA, the phase 3 trial end points and assay readouts have been harmonized through a collaborative effort involving the National Institute of Allergy and Infectious Diseases (NIAID), the erectile dysfunction Prevention Network, OWS, and the sponsor companies.Finally, OWS is supporting the companies financially and technically to commence process development and scale up manufacturing while their treatments are in preclinical or very early clinical stages.
To ensure that industrial processes are set, running, and validated for FDA inspection when phase 3 trials end, OWS is also supporting facility building or refurbishing, equipment fitting, staff hiring and training, raw-material sourcing, technology transfer and validation, bulk product processing into vials, and acquisition of ample vials, syringes, and needles for each treatment candidate. We aim to have stockpiled, at OWSâs expense, a few tens of millions of treatment doses that could be swiftly deployed once FDA approval is obtained.This strategy aims to accelerate treatment development without curtailing the critical steps required by sound science and regulatory standards. The FDA recently reissued guidance and standards that will be used to assess each treatment for a Biologics License Application (BLA). Alternatively, the agency could decide to issue an Emergency Use Authorization to permit treatment administration before all BLA procedures are completed.Of the eight treatments in OWSâs portfolio, six have been announced and partnerships executed with the companies.
Moderna and Pfizer/BioNTech (both mRNA), AstraZeneca and Janssen (both replication-defective live-vector), and Novavax and Sanofi/GSK (both recombinant-subunit-adjuvanted protein). These candidates cover three of the four platform technologies and are currently in clinical trials. The remaining two candidates will enter trials soon.Moderna developed its RNA treatment in collaboration with the NIAID, began its phase 1 trial in March, recently published encouraging safety and immunogenicity data,1 and entered phase 3 on July 27. Pfizer and BioNTechâs RNA treatment also produced encouraging phase 1 results2 and started its phase 3 trial on July 27.
The ChAdOx replication-defective live-vector treatment developed by AstraZeneca and Oxford University is in phase 3 trials in the United Kingdom, Brazil, and South Africa, and it should enter U.S. Phase 3 trials in August.3 The Janssen Ad26 erectile dysfunction treatment replication-defective live-vector treatment has demonstrated excellent protection in nonhuman primate models and began its U.S. Phase 1 trial on July 27. It should be in phase 3 trials in mid-September.
Novavax completed a phase 1 trial of its recombinant-subunit-adjuvanted protein treatment in Australia and should enter phase 3 trials in the United States by the end of September.4 Sanofi/GSK is completing preclinical development steps and plans to commence a phase 1 trial in early September and to be well into phase 3 by yearâs end.5On the process-development front, the RNA treatments are already being manufactured at scale. The other candidates are well advanced in their scale-up development, and manufacturing sites are being refurbished.While development and manufacturing proceed, the HHSâDOD partnership is laying the groundwork for treatment distribution, subpopulation prioritization, financing, and logistic support. We are working with bioethicists and experts from the NIH, the CDC, BARDA, and the Centers for Medicare and Medicaid Services to address these critical issues. We will receive recommendations from the CDC Advisory Committee on Immunization Practices, and we are working to ensure that the most vulnerable and at-risk persons will receive treatment doses once they are ready.
Prioritization will also depend on the relative performance of each treatment and its suitability for particular populations. Because some technologies have limited previous data on safety in humans, the long-term safety of these treatments will be carefully assessed using pharmacovigilance surveillance strategies.No scientific enterprise could guarantee success by January 2021, but the strategic decisions and choices weâve made, the support the government has provided, and the accomplishments to date make us optimistic that we will succeed in this unprecedented endeavor.Trial Design and Oversight We conducted a randomized, double-blind, placebo-controlled trial to evaluate postexposure prophylaxis with hydroxychloroquine after exposure to erectile dysfunction treatment.12 We randomly assigned participants in a 1:1 ratio to receive either hydroxychloroquine or placebo. Participants had known exposure (by participant report) to a person with laboratory-confirmed erectile dysfunction treatment, whether as a household contact, a health care worker, or a person with other occupational exposures. Trial enrollment began on March 17, 2020, with an eligibility threshold to enroll within 3 days after exposure.
The objective was to intervene before the median incubation period of 5 to 6 days. Because of limited access to prompt testing, health care workers could initially be enrolled on the basis of presumptive high-risk exposure to patients with pending tests. However, on March 23, eligibility was changed to exposure to a person with a positive polymerase-chain-reaction (PCR) assay for erectile dysfunction, with the eligibility window extended to within 4 days after exposure. This trial was approved by the institutional review board at the University of Minnesota and conducted under a Food and Drug Administration Investigational New Drug application.
In Canada, the trial was approved by Health Canada. Ethics approvals were obtained from the Research Institute of the McGill University Health Centre, the University of Manitoba, and the University of Alberta. Participants We included participants who had household or occupational exposure to a person with confirmed erectile dysfunction treatment at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Participants were excluded if they were younger than 18 years of age, were hospitalized, or met other exclusion criteria (see the Supplementary Appendix, available with the full text of this article at NEJM.org).
Persons with symptoms of erectile dysfunction treatment or with PCR-proven erectile dysfunction were excluded from this prevention trial but were separately enrolled in a companion clinical trial to treat early . Setting Recruitment was performed primarily with the use of social media outreach as well as traditional media platforms. Participants were enrolled nationwide in the United States and in the Canadian provinces of Quebec, Manitoba, and Alberta. Participants enrolled themselves through a secure Internet-based survey using the Research Electronic Data Capture (REDCap) system.13 After participants read the consent form, their comprehension of its contents was assessed.
Participants provided a digitally captured signature to indicate informed consent. We sent follow-up e-mail surveys on days 1, 5, 10, and 14. A survey at 4 to 6 weeks asked about any follow-up testing, illness, or hospitalizations. Participants who did not respond to follow-up surveys received text messages, e-mails, telephone calls, or a combination of these to ascertain their outcomes.
When these methods were unsuccessful, the emergency contact provided by the enrollee was contacted to determine the participantâs illness and vital status. When all communication methods were exhausted, Internet searches for obituaries were performed to ascertain vital status. Interventions Randomization occurred at research pharmacies in Minneapolis and Montreal. The trial statisticians generated a permuted-block randomization sequence using variably sized blocks of 2, 4, or 8, with stratification according to country.
A research pharmacist sequentially assigned participants. The assignments were concealed from investigators and participants. Only pharmacies had access to the randomization sequence. Hydroxychloroquine sulfate or placebo was dispensed and shipped overnight to participants by commercial courier.
The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total). If participants had gastrointestinal upset, they were advised to divide the daily dose into two or three doses. We chose this hydroxychloroquine dosing regimen on the basis of pharmacokinetic simulations to achieve plasma concentrations above the erectile dysfunction in vitro half maximal effective concentration for 14 days.14 Placebo folate tablets, which were similar in appearance to the hydroxychloroquine tablets, were prescribed as an identical regimen for the control group. Rising Pharmaceuticals provided a donation of hydroxychloroquine, and some hydroxychloroquine was purchased.
Outcomes The primary outcome was prespecified as symptomatic illness confirmed by a positive molecular assay or, if testing was unavailable, erectile dysfunction treatmentârelated symptoms. We assumed that health care workers would have access to erectile dysfunction treatment testing if symptomatic. However, access to testing was limited throughout the trial period. erectile dysfunction treatmentârelated symptoms were based on U.S.
Council for State and Territorial Epidemiologists criteria for confirmed cases (positivity for erectile dysfunction on PCR assay), probable cases (the presence of cough, shortness of breath, or difficulty breathing, or the presence of two or more symptoms of fever, chills, rigors, myalgia, headache, sore throat, and new olfactory and taste disorders), and possible cases (the presence of one or more compatible symptoms, which could include diarrhea).15 All the participants had epidemiologic linkage,15 per trial eligibility criteria. Four infectious disease physicians who were unaware of the trial-group assignments reviewed symptomatic participants to generate a consensus with respect to whether their condition met the case definition.15 Secondary outcomes included the incidence of hospitalization for erectile dysfunction treatment or death, the incidence of PCR-confirmed erectile dysfunction , the incidence of erectile dysfunction treatment symptoms, the incidence of discontinuation of the trial intervention owing to any cause, and the severity of symptoms (if any) at days 5 and 14 according to a visual analogue scale (scores ranged from 0 [no symptoms] to 10 [severe symptoms]). Data on adverse events were also collected with directed questioning for common side effects along with open-ended free text. Outcome data were measured within 14 days after trial enrollment.
Outcome data including PCR testing results, possible erectile dysfunction treatmentârelated symptoms, adherence to the trial intervention, side effects, and hospitalizations were all collected through participant report. Details of trial conduct are provided in the protocol and statistical analysis plan, available at NEJM.org. Sample Size We anticipated that illness compatible with erectile dysfunction treatment would develop in 10% of close contacts exposed to erectile dysfunction treatment.9 Using Fisherâs exact method with a 50% relative effect size to reduce new symptomatic s, a two-sided alpha of 0.05, and 90% power, we estimated that 621 persons would need to be enrolled in each group. With a pragmatic, Internet-based, self-referral recruitment strategy, we planned for a 20% incidence of attrition by increasing the sample size to 750 participants per group.
We specified a priori that participants who were already symptomatic on day 1 before receiving hydroxychloroquine or placebo would be excluded from the prophylaxis trial and would instead be separately enrolled in the companion symptomatic treatment trial. Because the estimates for both incident symptomatic erectile dysfunction treatment after an exposure and loss to follow-up were relatively unknown in early March 2020,9 the protocol prespecified a sample-size reestimation at the second interim analysis. This reestimation, which used the incidence of new s in the placebo group and the observed percentage of participants lost to follow-up, was aimed at maintaining the ability to detect an effect size of a 50% relative reduction in new symptomatic s. Interim Analyses An independent data and safety monitoring board externally reviewed the data after 25% and 50% of the participants had completed 14 days of follow-up.
Stopping guidelines were provided to the data and safety monitoring board with the use of a LanâDeMets spending function analogue of the OâBrienâFleming boundaries for the primary outcome. A conditional power analysis was performed at the second and third interim analysis with the option of early stopping for futility. At the second interim analysis on April 22, 2020, the sample size was reduced to 956 participants who could be evaluated with 90% power on the basis of the higher-than-expected event rate of s in the control group. At the third interim analysis on May 6, the trial was halted on the basis of a conditional power of less than 1%, since it was deemed futile to continue.
Statistical Analysis We assessed the incidence of erectile dysfunction treatment disease by day 14 with Fisherâs exact test. Secondary outcomes with respect to percentage of patients were also compared with Fisherâs exact test. Among participants in whom incident illness compatible with erectile dysfunction treatment developed, we summarized the symptom severity score at day 14 with the median and interquartile range and assessed the distributions with a KruskalâWallis test. We conducted all analyses with SAS software, version 9.4 (SAS Institute), according to the intention-to-treat principle, with two-sided type I error with an alpha of 0.05.
For participants with missing outcome data, we conducted a sensitivity analysis with their outcomes excluded or included as an event. Subgroups that were specified a priori included type of contact (household vs. Health care), days from exposure to enrollment, age, and sex.Trial Design and Oversight The RECOVERY trial was designed to evaluate the effects of potential treatments in patients hospitalized with erectile dysfunction treatment at 176 National Health Service organizations in the United Kingdom and was supported by the National Institute for Health Research Clinical Research Network. (Details regarding this trial are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.) The trial is being coordinated by the Nuffield Department of Population Health at the University of Oxford, the trial sponsor.
Although the randomization of patients to receive dexamethasone, hydroxychloroquine, or lopinavirâritonavir has now been stopped, the trial continues randomization to groups receiving azithromycin, tocilizumab, or convalescent plasma. Hospitalized patients were eligible for the trial if they had clinically suspected or laboratory-confirmed erectile dysfunction and no medical history that might, in the opinion of the attending clinician, put patients at substantial risk if they were to participate in the trial. Initially, recruitment was limited to patients who were at least 18 years of age, but the age limit was removed starting on May 9, 2020. Pregnant or breast-feeding women were eligible.
Written informed consent was obtained from all the patients or from a legal representative if they were unable to provide consent. The trial was conducted in accordance with the principles of the Good Clinical Practice guidelines of the International Conference on Harmonisation and was approved by the U.K. Medicines and Healthcare Products Regulatory Agency and the Cambridge East Research Ethics Committee. The protocol with its statistical analysis plan is available at NEJM.org and on the trial website at www.recoverytrial.net.
The initial version of the manuscript was drafted by the first and last authors, developed by the writing committee, and approved by all members of the trial steering committee. The funders had no role in the analysis of the data, in the preparation or approval of the manuscript, or in the decision to submit the manuscript for publication. The first and last members of the writing committee vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol and statistical analysis plan. Randomization We collected baseline data using a Web-based case-report form that included demographic data, the level of respiratory support, major coexisting illnesses, suitability of the trial treatment for a particular patient, and treatment availability at the trial site.
Randomization was performed with the use of a Web-based system with concealment of the trial-group assignment. Eligible and consenting patients were assigned in a 2:1 ratio to receive either the usual standard of care alone or the usual standard of care plus oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days (or until hospital discharge if sooner) or to receive one of the other suitable and available treatments that were being evaluated in the trial. For some patients, dexamethasone was unavailable at the hospital at the time of enrollment or was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from entry in the randomized comparison between dexamethasone and usual care and hence were not included in this report.
The randomly assigned treatment was prescribed by the treating clinician. Patients and local members of the trial staff were aware of the assigned treatments. Procedures A single online follow-up form was to be completed when the patients were discharged or had died or at 28 days after randomization, whichever occurred first. Information was recorded regarding the patientsâ adherence to the assigned treatment, receipt of other trial treatments, duration of admission, receipt of respiratory support (with duration and type), receipt of renal support, and vital status (including the cause of death).
In addition, we obtained routine health care and registry data, including information on vital status (with date and cause of death), discharge from the hospital, and respiratory and renal support therapy. Outcome Measures The primary outcome was all-cause mortality within 28 days after randomization. Further analyses were specified at 6 months. Secondary outcomes were the time until discharge from the hospital and, among patients not receiving invasive mechanical ventilation at the time of randomization, subsequent receipt of invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death.
Other prespecified clinical outcomes included cause-specific mortality, receipt of renal hemodialysis or hemofiltration, major cardiac arrhythmia (recorded in a subgroup), and receipt and duration of ventilation. Statistical Analysis As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned at the start of the erectile dysfunction treatment kamagra. As the trial progressed, the trial steering committee, whose members were unaware of the results of the trial comparisons, determined that if 28-day mortality was 20%, then the enrollment of at least 2000 patients in the dexamethasone group and 4000 in the usual care group would provide a power of at least 90% at a two-sided P value of 0.01 to detect a clinically relevant proportional reduction of 20% (an absolute difference of 4 percentage points) between the two groups. Consequently, on June 8, 2020, the steering committee closed recruitment to the dexamethasone group, since enrollment had exceeded 2000 patients.
For the primary outcome of 28-day mortality, the hazard ratio from Cox regression was used to estimate the mortality rate ratio. Among the few patients (0.1%) who had not been followed for 28 days by the time of the data cutoff on July 6, 2020, data were censored either on that date or on day 29 if the patient had already been discharged. That is, in the absence of any information to the contrary, these patients were assumed to have survived for 28 days. KaplanâMeier survival curves were constructed to show cumulative mortality over the 28-day period.
Cox regression was used to analyze the secondary outcome of hospital discharge within 28 days, with censoring of data on day 29 for patients who had died during hospitalization. For the prespecified composite secondary outcome of invasive mechanical ventilation or death within 28 days (among patients who were not receiving invasive mechanical ventilation at randomization), the precise date of invasive mechanical ventilation was not available, so a log-binomial regression model was used to estimate the risk ratio. Table 1. Table 1.
Characteristics of the Patients at Baseline, According to Treatment Assignment and Level of Respiratory Support. Through the play of chance in the unstratified randomization, the mean age was 1.1 years older among patients in the dexamethasone group than among those in the usual care group (Table 1). To account for this imbalance in an important prognostic factor, estimates of rate ratios were adjusted for the baseline age in three categories (<70 years, 70 to 79 years, and â¥80 years). This adjustment was not specified in the first version of the statistical analysis plan but was added once the imbalance in age became apparent.
Results without age adjustment (corresponding to the first version of the analysis plan) are provided in the Supplementary Appendix. Prespecified analyses of the primary outcome were performed in five subgroups, as defined by characteristics at randomization. Age, sex, level of respiratory support, days since symptom onset, and predicted 28-day mortality risk. (One further prespecified subgroup analysis regarding race will be conducted once the data collection has been completed.) In prespecified subgroups, we estimated rate ratios (or risk ratios in some analyses) and their confidence intervals using regression models that included an interaction term between the treatment assignment and the subgroup of interest.
Chi-square tests for linear trend across the subgroup-specific log estimates were then performed in accordance with the prespecified plan. All P values are two-sided and are shown without adjustment for multiple testing. All analyses were performed according to the intention-to-treat principle. The full database is held by the trial team, which collected the data from trial sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford..
Trial Population how do i get kamagra Table 1. Table 1. Characteristics of the Participants in the mRNA-1273 Trial how do i get kamagra at Enrollment. The 45 enrolled participants received their first vaccination between March 16 and April 14, 2020 (Fig.
S1). Three participants did not receive the second vaccination, including one in the 25-μg group who had urticaria on both legs, with onset 5 days after the first vaccination, and two (one in the 25-μg group and one in the 250-μg group) who missed the second vaccination window owing to isolation for suspected erectile dysfunction treatment while the test results, ultimately negative, were pending. All continued to attend scheduled trial visits. The demographic characteristics of participants at enrollment are provided in Table 1.
treatment Safety No serious adverse events were noted, and no prespecified trial halting rules were met. As noted above, one participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient urticaria, judged to be related to the first vaccination. Figure 1. Figure 1.
Systemic and Local Adverse Events. The severity of solicited adverse events was graded as mild, moderate, or severe (see Table S1).After the first vaccination, solicited systemic adverse events were reported by 5 participants (33%) in the 25-μg group, 10 (67%) in the 100-μg group, and 8 (53%) in the 250-μg group. All were mild or moderate in severity (Figure 1 and Table S2). Solicited systemic adverse events were more common after the second vaccination and occurred in 7 of 13 participants (54%) in the 25-μg group, all 15 in the 100-μg group, and all 14 in the 250-μg group, with 3 of those participants (21%) reporting one or more severe events.
None of the participants had fever after the first vaccination. After the second vaccination, no participants in the 25-μg group, 6 (40%) in the 100-μg group, and 8 (57%) in the 250-μg group reported fever. One of the events (maximum temperature, 39.6°C) in the 250-μg group was graded severe. (Additional details regarding adverse events for that participant are provided in the Supplementary Appendix.) Local adverse events, when present, were nearly all mild or moderate, and pain at the injection site was common.
Across both vaccinations, solicited systemic and local adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Evaluation of safety clinical laboratory values of grade 2 or higher and unsolicited adverse events revealed no patterns of concern (Supplementary Appendix and Table S3). erectile dysfunction Binding Antibody Responses Table 2. Table 2.
Geometric Mean Humoral Immunogenicity Assay Responses to mRNA-1273 in Participants and in Convalescent Serum Specimens. Figure 2. Figure 2. erectile dysfunction Antibody and Neutralization Responses.
Shown are geometric mean reciprocal end-point enzyme-linked immunosorbent assay (ELISA) IgG titers to S-2P (Panel A) and receptor-binding domain (Panel B), PsVNA ID50 responses (Panel C), and live kamagra PRNT80 responses (Panel D). In Panel A and Panel B, boxes and horizontal bars denote interquartile range (IQR) and median area under the curve (AUC), respectively. Whisker endpoints are equal to the maximum and minimum values below or above the median ±1.5 times the IQR. The convalescent serum panel includes specimens from 41 participants.
Red dots indicate the 3 specimens that were also tested in the PRNT assay. The other 38 specimens were used to calculate summary statistics for the box plot in the convalescent serum panel. In Panel C, boxes and horizontal bars denote IQR and median ID50, respectively. Whisker end points are equal to the maximum and minimum values below or above the median ±1.5 times the IQR.
In the convalescent serum panel, red dots indicate the 3 specimens that were also tested in the PRNT assay. The other 38 specimens were used to calculate summary statistics for the box plot in the convalescent panel. In Panel D, boxes and horizontal bars denote IQR and median PRNT80, respectively. Whisker end points are equal to the maximum and minimum values below or above the median ±1.5 times the IQR.
The three convalescent serum specimens were also tested in ELISA and PsVNA assays. Because of the time-intensive nature of the PRNT assay, for this preliminary report, PRNT results were available only for the 25-μg and 100-μg dose groups.Binding antibody IgG geometric mean titers (GMTs) to S-2P increased rapidly after the first vaccination, with seroconversion in all participants by day 15 (Table 2 and Figure 2A). Dose-dependent responses to the first and second vaccinations were evident. Receptor-binding domainâspecific antibody responses were similar in pattern and magnitude (Figure 2B).
For both assays, the median magnitude of antibody responses after the first vaccination in the 100-μg and 250-μg dose groups was similar to the median magnitude in convalescent serum specimens, and in all dose groups the median magnitude after the second vaccination was in the upper quartile of values in the convalescent serum specimens. The S-2P ELISA GMTs at day 57 (299,751 [95% confidence interval {CI}, 206,071 to 436,020] in the 25-μg group, 782,719 [95% CI, 619,310 to 989,244] in the 100-μg group, and 1,192,154 [95% CI, 924,878 to 1,536,669] in the 250-μg group) exceeded that in the convalescent serum specimens (142,140 [95% CI, 81,543 to 247,768]). erectile dysfunction Neutralization Responses No participant had detectable PsVNA responses before vaccination. After the first vaccination, PsVNA responses were detected in less than half the participants, and a dose effect was seen (50% inhibitory dilution [ID50].
Figure 2C, Fig. S8, and Table 2. 80% inhibitory dilution [ID80]. Fig.
S2 and Table S6). However, after the second vaccination, PsVNA responses were identified in serum samples from all participants. The lowest responses were in the 25-μg dose group, with a geometric mean ID50 of 112.3 (95% CI, 71.2 to 177.1) at day 43. The higher responses in the 100-μg and 250-μg groups were similar in magnitude (geometric mean ID50, 343.8 [95% CI, 261.2 to 452.7] and 332.2 [95% CI, 266.3 to 414.5], respectively, at day 43).
These responses were similar to values in the upper half of the distribution of values for convalescent serum specimens. Before vaccination, no participant had detectable 80% live-kamagra neutralization at the highest serum concentration tested (1:8 dilution) in the PRNT assay. At day 43, wild-type kamagraâneutralizing activity capable of reducing erectile dysfunction infectivity by 80% or more (PRNT80) was detected in all participants, with geometric mean PRNT80 responses of 339.7 (95% CI, 184.0 to 627.1) in the 25-μg group and 654.3 (95% CI, 460.1 to 930.5) in the 100-μg group (Figure 2D). Neutralizing PRNT80 average responses were generally at or above the values of the three convalescent serum specimens tested in this assay.
Good agreement was noted within and between the values from binding assays for S-2P and receptor-binding domain and neutralizing activity measured by PsVNA and PRNT (Figs. S3 through S7), which provides orthogonal support for each assay in characterizing the humoral response induced by mRNA-1273. erectile dysfunction T-Cell Responses The 25-μg and 100-μg doses elicited CD4 T-cell responses (Figs. S9 and S10) that on stimulation by S-specific peptide pools were strongly biased toward expression of Th1 cytokines (tumor necrosis factor α >.
Interleukin 2 >. Interferon γ), with minimal type 2 helper T-cell (Th2) cytokine expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels after the second vaccination in the 100-μg dose group (Fig. S11).Patients Figure 1.
Figure 1. Enrollment and Randomization. Of the 1107 patients who were assessed for eligibility, 1063 underwent randomization. 541 were assigned to the remdesivir group and 522 to the placebo group (Figure 1).
Of those assigned to receive remdesivir, 531 patients (98.2%) received the treatment as assigned. Forty-nine patients had remdesivir treatment discontinued before day 10 because of an adverse event or a serious adverse event other than death (36 patients) or because the patient withdrew consent (13). Of those assigned to receive placebo, 518 patients (99.2%) received placebo as assigned. Fifty-three patients discontinued placebo before day 10 because of an adverse event or a serious adverse event other than death (36 patients), because the patient withdrew consent (15), or because the patient was found to be ineligible for trial enrollment (2).
As of April 28, 2020, a total of 391 patients in the remdesivir group and 340 in the placebo group had completed the trial through day 29, recovered, or died. Eight patients who received remdesivir and 9 who received placebo terminated their participation in the trial before day 29. There were 132 patients in the remdesivir group and 169 in the placebo group who had not recovered and had not completed the day 29 follow-up visit. The analysis population included 1059 patients for whom we have at least some postbaseline data available (538 in the remdesivir group and 521 in the placebo group).
Four of the 1063 patients were not included in the primary analysis because no postbaseline data were available at the time of the database freeze. Table 1. Table 1. Demographic and Clinical Characteristics at Baseline.
The mean age of patients was 58.9 years, and 64.3% were male (Table 1). On the basis of the evolving epidemiology of erectile dysfunction treatment during the trial, 79.8% of patients were enrolled at sites in North America, 15.3% in Europe, and 4.9% in Asia (Table S1). Overall, 53.2% of the patients were white, 20.6% were black, 12.6% were Asian, and 13.6% were designated as other or not reported. 249 (23.4%) were Hispanic or Latino.
Most patients had either one (27.0%) or two or more (52.1%) of the prespecified coexisting conditions at enrollment, most commonly hypertension (49.6%), obesity (37.0%), and type 2 diabetes mellitus (29.7%). The median number of days between symptom onset and randomization was 9 (interquartile range, 6 to 12). Nine hundred forty-three (88.7%) patients had severe disease at enrollment as defined in the Supplementary Appendix. 272 (25.6%) patients met category 7 criteria on the ordinal scale, 197 (18.5%) category 6, 421 (39.6%) category 5, and 127 (11.9%) category 4.
There were 46 (4.3%) patients who had missing ordinal scale data at enrollment. No substantial imbalances in baseline characteristics were observed between the remdesivir group and the placebo group. Primary Outcome Figure 2. Figure 2.
KaplanâMeier Estimates of Cumulative Recoveries. Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale (not receiving oxygen. Panel B), in those with a baseline score of 5 (receiving oxygen. Panel C), in those with a baseline score of 6 (receiving high-flow oxygen or noninvasive mechanical ventilation.
Panel D), and in those with a baseline score of 7 (receiving mechanical ventilation or ECMO. Panel E). Table 2. Table 2.
Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population. Figure 3. Figure 3. Time to Recovery According to Subgroup.
The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. Race and ethnic group were reported by the patients. Patients in the remdesivir group had a shorter time to recovery than patients in the placebo group (median, 11 days, as compared with 15 days. Rate ratio for recovery, 1.32.
95% confidence interval [CI], 1.12 to 1.55. P<0.001. 1059 patients (Figure 2 and Table 2). Among patients with a baseline ordinal score of 5 (421 patients), the rate ratio for recovery was 1.47 (95% CI, 1.17 to 1.84).
Among patients with a baseline score of 4 (127 patients) and those with a baseline score of 6 (197 patients), the rate ratio estimates for recovery were 1.38 (95% CI, 0.94 to 2.03) and 1.20 (95% CI, 0.79 to 1.81), respectively. For those receiving mechanical ventilation or ECMO at enrollment (baseline ordinal scores of 7. 272 patients), the rate ratio for recovery was 0.95 (95% CI, 0.64 to 1.42). A test of interaction of treatment with baseline score on the ordinal scale was not significant.
An analysis adjusting for baseline ordinal score as a stratification variable was conducted to evaluate the overall effect (of the percentage of patients in each ordinal score category at baseline) on the primary outcome. This adjusted analysis produced a similar treatment-effect estimate (rate ratio for recovery, 1.31. 95% CI, 1.12 to 1.54. 1017 patients).
Table S2 in the Supplementary Appendix shows results according to the baseline severity stratum of mild-to-moderate as compared with severe. Patients who underwent randomization during the first 10 days after the onset of symptoms had a rate ratio for recovery of 1.28 (95% CI, 1.05 to 1.57. 664 patients), whereas patients who underwent randomization more than 10 days after the onset of symptoms had a rate ratio for recovery of 1.38 (95% CI, 1.05 to 1.81. 380 patients) (Figure 3).
Key Secondary Outcome The odds of improvement in the ordinal scale score were higher in the remdesivir group, as determined by a proportional odds model at the day 15 visit, than in the placebo group (odds ratio for improvement, 1.50. 95% CI, 1.18 to 1.91. P=0.001. 844 patients) (Table 2 and Fig.
S5). Mortality was numerically lower in the remdesivir group than in the placebo group, but the difference was not significant (hazard ratio for death, 0.70. 95% CI, 0.47 to 1.04. 1059 patients).
The KaplanâMeier estimates of mortality by 14 days were 7.1% and 11.9% in the remdesivir and placebo groups, respectively (Table 2). The KaplanâMeier estimates of mortality by 28 days are not reported in this preliminary analysis, given the large number of patients that had yet to complete day 29 visits. An analysis with adjustment for baseline ordinal score as a stratification variable showed a hazard ratio for death of 0.74 (95% CI, 0.50 to 1.10). Safety Outcomes Serious adverse events occurred in 114 patients (21.1%) in the remdesivir group and 141 patients (27.0%) in the placebo group (Table S3).
4 events (2 in each group) were judged by site investigators to be related to remdesivir or placebo. There were 28 serious respiratory failure adverse events in the remdesivir group (5.2% of patients) and 42 in the placebo group (8.0% of patients). Acute respiratory failure, hypotension, viral pneumonia, and acute kidney injury were slightly more common among patients in the placebo group. No deaths were considered to be related to treatment assignment, as judged by the site investigators.
Grade 3 or 4 adverse events occurred in 156 patients (28.8%) in the remdesivir group and in 172 in the placebo group (33.0%) (Table S4). The most common adverse events in the remdesivir group were anemia or decreased hemoglobin (43 events [7.9%], as compared with 47 [9.0%] in the placebo group). Acute kidney injury, decreased estimated glomerular filtration rate or creatinine clearance, or increased blood creatinine (40 events [7.4%], as compared with 38 [7.3%]). Pyrexia (27 events [5.0%], as compared with 17 [3.3%]).
Hyperglycemia or increased blood glucose level (22 events [4.1%], as compared with 17 [3.3%]). And increased aminotransferase levels including alanine aminotransferase, aspartate aminotransferase, or both (22 events [4.1%], as compared with 31 [5.9%]). Otherwise, the incidence of adverse events was not found to be significantly different between the remdesivir group and the placebo group.Announced on May 15, Operation Warp Speed (OWS) â a partnership of the Department of Health and Human Services (HHS), the Department of Defense (DOD), and the private sector â aims to accelerate control of the erectile dysfunction treatment kamagra by advancing development, manufacturing, and distribution of treatments, therapeutics, and diagnostics. OWS is providing support to promising candidates and enabling the expeditious, parallel execution of the necessary steps toward approval or authorization of safe products by the Food and Drug Administration (FDA).The partnership grew out of an acknowledged need to fundamentally restructure the way the U.S.
Government typically supports product development and treatment distribution. The initiative was premised on setting a âstretch goalâ â one that initially seemed impossible but that is becoming increasingly achievable.The concept of an integrated structure for erectile dysfunction treatment countermeasure research and development across the U.S. Government was based on experience with Zika and the Zika Leadership Group led by the National Institutes of Health (NIH) and the assistant secretary for preparedness and response (ASPR). One of us (M.S.) serves as OWS chief advisor.
We are drawing on expertise from the NIH, ASPR, the Centers for Disease Control and Prevention (CDC), the Biomedical Advanced Research and Development Authority (BARDA), and the DOD, including the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and the Defense Advanced Research Projects Agency. OWS has engaged experts in all critical aspects of medical countermeasure research, development, manufacturing, and distribution to work in close coordination.The initiative set ambitious objectives. To deliver tens of millions of doses of a erectile dysfunction treatment â with demonstrated safety and efficacy, and approved or authorized by the FDA for use in the U.S. Population â beginning at the end of 2020 and to have as many as 300 million doses of such treatments available and deployed by mid-2021.
The pace and scope of such a treatment effort are unprecedented. The 2014 West African Ebola kamagra epidemic spurred rapid treatment development, but though preclinical data existed before the outbreak, a period of 12 months was required to progress from phase 1 first-in-human trials to phase 3 efficacy trials. OWS aims to compress this time frame even further. erectile dysfunction treatment development began in January, phase 1 clinical studies in March, and the first phase 3 trials in July.
Our objectives are based on advances in treatment platform technology, improved understanding of safe and efficacious treatment design, and similarities between the SARS-CoV-1 and erectile dysfunction disease mechanisms.OWSâs role is to enable, accelerate, harmonize, and advise the companies developing the selected treatments. The companies will execute the clinical or process development and manufacturing plans, while OWS leverages the full capacity of the U.S. Government to ensure that no technical, logistic, or financial hurdles hinder treatment development or deployment.OWS selected treatment candidates on the basis of four criteria. We required candidates to have robust preclinical data or early-stage clinical trial data supporting their potential for clinical safety and efficacy.
Candidates had to have the potential, with our acceleration support, to enter large phase 3 field efficacy trials this summer or fall (July to November 2020) and, assuming continued active transmission of the kamagra, to deliver efficacy outcomes by the end of 2020 or the first half of 2021. Candidates had to be based on treatment-platform technologies permitting fast and effective manufacturing, and their developers had to demonstrate the industrial process scalability, yields, and consistency necessary to reliably produce more than 100 million doses by mid-2021. Finally, candidates had to use one of four treatment-platform technologies that we believe are the most likely to yield a safe and effective treatment against erectile dysfunction treatment. The mRNA platform, the replication-defective live-vector platform, the recombinant-subunit-adjuvanted protein platform, or the attenuated replicating live-vector platform.OWSâs strategy relies on a few key principles.
First, we sought to build a diverse project portfolio that includes two treatment candidates based on each of the four platform technologies. Such diversification mitigates the risk of failure due to safety, efficacy, industrial manufacturability, or scheduling factors and may permit selection of the best treatment platform for each subpopulation at risk for contracting or transmitting erectile dysfunction treatment, including older adults, frontline and essential workers, young adults, and pediatric populations. In addition, advancing eight treatments in parallel will increase the chances of delivering 300 million doses in the first half of 2021.Second, we must accelerate treatment program development without compromising safety, efficacy, or product quality. Clinical development, process development, and manufacturing scale-up can be substantially accelerated by running all streams, fully resourced, in parallel.
Doing so requires taking on substantial financial risk, as compared with the conventional sequential development approach. OWS will maximize the size of phase 3 trials (30,000 to 50,000 participants each) and optimize trial-site location by consulting daily epidemiologic and disease-forecasting models to ensure the fastest path to an efficacy readout. Such large trials also increase the safety data set for each candidate treatment.With heavy up-front investment, companies can conduct clinical operations and site preparation for these phase 3 efficacy trials even as they file their Investigational New Drug application (IND) for their phase 1 studies, thereby ensuring immediate initiation of phase 3 when they get a green light from the FDA. To permit appropriate comparisons among the treatment candidates and to optimize treatment utilization after approval by the FDA, the phase 3 trial end points and assay readouts have been harmonized through a collaborative effort involving the National Institute of Allergy and Infectious Diseases (NIAID), the erectile dysfunction Prevention Network, OWS, and the sponsor companies.Finally, OWS is supporting the companies financially and technically to commence process development and scale up manufacturing while their treatments are in preclinical or very early clinical stages.
To ensure that industrial processes are set, running, and validated for FDA inspection when phase 3 trials end, OWS is also supporting facility building or refurbishing, equipment fitting, staff hiring and training, raw-material sourcing, technology transfer and validation, bulk product processing into vials, and acquisition of ample vials, syringes, and needles for each treatment candidate. We aim to have stockpiled, at OWSâs expense, a few tens of millions of treatment doses that could be swiftly deployed once FDA approval is obtained.This strategy aims to accelerate treatment development without curtailing the critical steps required by sound science and regulatory standards. The FDA recently reissued guidance and standards that will be used to assess each treatment for a Biologics License Application (BLA). Alternatively, the agency could decide to issue an Emergency Use Authorization to permit treatment administration before all BLA procedures are completed.Of the eight treatments in OWSâs portfolio, six have been announced and partnerships executed with the companies.
Moderna and Pfizer/BioNTech (both mRNA), AstraZeneca and Janssen (both replication-defective live-vector), and Novavax and Sanofi/GSK (both recombinant-subunit-adjuvanted protein). These candidates cover three of the four platform technologies and are currently in clinical trials. The remaining two candidates will enter trials soon.Moderna developed its RNA treatment in collaboration with the NIAID, began its phase 1 trial in March, recently published encouraging safety and immunogenicity data,1 and entered phase 3 on July 27. Pfizer and BioNTechâs RNA treatment also produced encouraging phase 1 results2 and started its phase 3 trial on July 27.
The ChAdOx replication-defective live-vector treatment developed by AstraZeneca and Oxford University is in phase 3 trials in the United Kingdom, Brazil, and South Africa, and it should enter U.S. Phase 3 trials in August.3 The Janssen Ad26 erectile dysfunction treatment replication-defective live-vector treatment has demonstrated excellent protection in nonhuman primate models and began its U.S. Phase 1 trial on July 27. It should be in phase 3 trials in mid-September.
Novavax completed a phase 1 trial of its recombinant-subunit-adjuvanted protein treatment in Australia and should enter phase 3 trials in the United States by the end of September.4 Sanofi/GSK is completing preclinical development steps and plans to commence a phase 1 trial in early September and to be well into phase 3 by yearâs end.5On the process-development front, the RNA treatments are already being manufactured at scale. The other candidates are well advanced in their scale-up development, and manufacturing sites are being refurbished.While development and manufacturing proceed, the HHSâDOD partnership is laying the groundwork for treatment distribution, subpopulation prioritization, financing, and logistic support. We are working with bioethicists and experts from the NIH, the CDC, BARDA, and the Centers for Medicare and Medicaid Services to address these critical issues. We will receive recommendations from the CDC Advisory Committee on Immunization Practices, and we are working to ensure that the most vulnerable and at-risk persons will receive treatment doses once they are ready.
Prioritization will also depend on the relative performance of each treatment and its suitability for particular populations. Because some technologies have limited previous data on safety in humans, the long-term safety of these treatments will be carefully assessed using pharmacovigilance surveillance strategies.No scientific enterprise could guarantee success by January 2021, but the strategic decisions and choices weâve made, the support the government has provided, and the accomplishments to date make us optimistic that we will succeed in this unprecedented endeavor.Trial Design and Oversight We conducted a randomized, double-blind, placebo-controlled trial to evaluate postexposure prophylaxis with hydroxychloroquine after exposure to erectile dysfunction treatment.12 We randomly assigned participants in a 1:1 ratio to receive either hydroxychloroquine or placebo. Participants had known exposure (by participant report) to a person with laboratory-confirmed erectile dysfunction treatment, whether as a household contact, a health care worker, or a person with other occupational exposures. Trial enrollment began on March 17, 2020, with an eligibility threshold to enroll within 3 days after exposure.
The objective was to intervene before the median incubation period of 5 to 6 days. Because of limited access to prompt testing, health care workers could initially be enrolled on the basis of presumptive high-risk exposure to patients with pending tests. However, on March 23, eligibility was changed to exposure to a person with a positive polymerase-chain-reaction (PCR) assay for erectile dysfunction, with the eligibility window extended to within 4 days after exposure. This trial was approved by the institutional review board at the University of Minnesota and conducted under a Food and Drug Administration Investigational New Drug application.
In Canada, the trial was approved by Health Canada. Ethics approvals were obtained from the Research Institute of the McGill University Health Centre, the University of Manitoba, and the University of Alberta. Participants We included participants who had household or occupational exposure to a person with confirmed erectile dysfunction treatment at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Participants were excluded if they were younger than 18 years of age, were hospitalized, or met other exclusion criteria (see the Supplementary Appendix, available with the full text of this article at NEJM.org).
Persons with symptoms of erectile dysfunction treatment or with PCR-proven erectile dysfunction were excluded from this prevention trial but were separately enrolled in a companion clinical trial to treat early . Setting Recruitment was performed primarily with the use of social media outreach as well as traditional media platforms. Participants were enrolled nationwide in the United States and in the Canadian provinces of Quebec, Manitoba, and Alberta. Participants enrolled themselves through a secure Internet-based survey using the Research Electronic Data Capture (REDCap) system.13 After participants read the consent form, their comprehension of its contents was assessed.
Participants provided a digitally captured signature to indicate informed consent. We sent follow-up e-mail surveys on days 1, 5, 10, and 14. A survey at 4 to 6 weeks asked about any follow-up testing, illness, or hospitalizations. Participants who did not respond to follow-up surveys received text messages, e-mails, telephone calls, or a combination of these to ascertain their outcomes.
When these methods were unsuccessful, the emergency contact provided by the enrollee was contacted to determine the participantâs illness and vital status. When all communication methods were exhausted, Internet searches for obituaries were performed to ascertain vital status. Interventions Randomization occurred at research pharmacies in Minneapolis and Montreal. The trial statisticians generated a permuted-block randomization sequence using variably sized blocks of 2, 4, or 8, with stratification according to country.
A research pharmacist sequentially assigned participants. The assignments were concealed from investigators and participants. Only pharmacies had access to the randomization sequence. Hydroxychloroquine sulfate or placebo was dispensed and shipped overnight to participants by commercial courier.
The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total). If participants had gastrointestinal upset, they were advised to divide the daily dose into two or three doses. We chose this hydroxychloroquine dosing regimen on the basis of pharmacokinetic simulations to achieve plasma concentrations above the erectile dysfunction in vitro half maximal effective concentration for 14 days.14 Placebo folate tablets, which were similar in appearance to the hydroxychloroquine tablets, were prescribed as an identical regimen for the control group. Rising Pharmaceuticals provided a donation of hydroxychloroquine, and some hydroxychloroquine was purchased.
Outcomes The primary outcome was prespecified as symptomatic illness confirmed by a positive molecular assay or, if testing was unavailable, erectile dysfunction treatmentârelated symptoms. We assumed that health care workers would have access to erectile dysfunction treatment testing if symptomatic. However, access to testing was limited throughout the trial period. erectile dysfunction treatmentârelated symptoms were based on U.S.
Council for State and Territorial Epidemiologists criteria for confirmed cases (positivity for erectile dysfunction on PCR assay), probable cases (the presence of cough, shortness of breath, or difficulty breathing, or the presence of two or more symptoms of fever, chills, rigors, myalgia, headache, sore throat, and new olfactory and taste disorders), and possible cases (the presence of one or more compatible symptoms, which could include diarrhea).15 All the participants had epidemiologic linkage,15 per trial eligibility criteria. Four infectious disease physicians who were unaware of the trial-group assignments reviewed symptomatic participants to generate a consensus with respect to whether their condition met the case definition.15 Secondary outcomes included the incidence of hospitalization for erectile dysfunction treatment or death, the incidence of PCR-confirmed erectile dysfunction , the incidence of erectile dysfunction treatment symptoms, the incidence of discontinuation of the trial intervention owing to any cause, and the severity of symptoms (if any) at days 5 and 14 according to a visual analogue scale (scores ranged from 0 [no symptoms] to 10 [severe symptoms]). Data on adverse events were also collected with directed questioning for common side effects along with open-ended free text. Outcome data were measured within 14 days after trial enrollment.
Outcome data including PCR testing results, possible erectile dysfunction treatmentârelated symptoms, adherence to the trial intervention, side effects, and hospitalizations were all collected through participant report. Details of trial conduct are provided in the protocol and statistical analysis plan, available at NEJM.org. Sample Size We anticipated that illness compatible with erectile dysfunction treatment would develop in 10% of close contacts exposed to erectile dysfunction treatment.9 Using Fisherâs exact method with a 50% relative effect size to reduce new symptomatic s, a two-sided alpha of 0.05, and 90% power, we estimated that 621 persons would need to be enrolled in each group. With a pragmatic, Internet-based, self-referral recruitment strategy, we planned for a 20% incidence of attrition by increasing the sample size to 750 participants per group.
We specified a priori that participants who were already symptomatic on day 1 before receiving hydroxychloroquine or placebo would be excluded from the prophylaxis trial and would instead be separately enrolled in the companion symptomatic treatment trial. Because the estimates for both incident symptomatic erectile dysfunction treatment after an exposure and loss to follow-up were relatively unknown in early March 2020,9 the protocol prespecified a sample-size reestimation at the second interim analysis. This reestimation, which used the incidence of new s in the placebo group and the observed percentage of participants lost to follow-up, was aimed at maintaining the ability to detect an effect size of a 50% relative reduction in new symptomatic s. Interim Analyses An independent data and safety monitoring board externally reviewed the data after 25% and 50% of the participants had completed 14 days of follow-up.
Stopping guidelines were provided to the data and safety monitoring board with the use of a LanâDeMets spending function analogue of the OâBrienâFleming boundaries for the primary outcome. A conditional power analysis was performed at the second and third interim analysis with the option of early stopping for futility. At the second interim analysis on April 22, 2020, the sample size was reduced to 956 participants who could be evaluated with 90% power on the basis of the higher-than-expected event rate of s in the control group. At the third interim analysis on May 6, the trial was halted on the basis of a conditional power of less than 1%, since it was deemed futile to continue.
Statistical Analysis We assessed the incidence of erectile dysfunction treatment disease by day 14 with Fisherâs exact test. Secondary outcomes with respect to percentage of patients were also compared with Fisherâs exact test. Among participants in whom incident illness compatible with erectile dysfunction treatment developed, we summarized the symptom severity score at day 14 with the median and interquartile range and assessed the distributions with a KruskalâWallis test. We conducted all analyses with SAS software, version 9.4 (SAS Institute), according to the intention-to-treat principle, with two-sided type I error with an alpha of 0.05.
For participants with missing outcome data, we conducted a sensitivity analysis with their outcomes excluded or included as an event. Subgroups that were specified a priori included type of contact (household vs. Health care), days from exposure to enrollment, age, and sex.Trial Design and Oversight The RECOVERY trial was designed to evaluate the effects of potential treatments in patients hospitalized with erectile dysfunction treatment at 176 National Health Service organizations in the United Kingdom and was supported by the National Institute for Health Research Clinical Research Network. (Details regarding this trial are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.) The trial is being coordinated by the Nuffield Department of Population Health at the University of Oxford, the trial sponsor.
Although the randomization of patients to receive dexamethasone, hydroxychloroquine, or lopinavirâritonavir has now been stopped, the trial continues randomization to groups receiving azithromycin, tocilizumab, or convalescent plasma. Hospitalized patients were eligible for the trial if they had clinically suspected or laboratory-confirmed erectile dysfunction and no medical history that might, in the opinion of the attending clinician, put patients at substantial risk if they were to participate in the trial. Initially, recruitment was limited to patients who were at least 18 years of age, but the age limit was removed starting on May 9, 2020. Pregnant or breast-feeding women were eligible.
Written informed consent was obtained from all the patients or from a legal representative if they were unable to provide consent. The trial was conducted in accordance with the principles of the Good Clinical Practice guidelines of the International Conference on Harmonisation and was approved by the U.K. Medicines and Healthcare Products Regulatory Agency and the Cambridge East Research Ethics Committee. The protocol with its statistical analysis plan is available at NEJM.org and on the trial website at www.recoverytrial.net.
The initial version of the manuscript was drafted by the first and last authors, developed by the writing committee, and approved by all members of the trial steering committee. The funders had no role in the analysis of the data, in the preparation or approval of the manuscript, or in the decision to submit the manuscript for publication. The first and last members of the writing committee vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol and statistical analysis plan. Randomization We collected baseline data using a Web-based case-report form that included demographic data, the level of respiratory support, major coexisting illnesses, suitability of the trial treatment for a particular patient, and treatment availability at the trial site.
Randomization was performed with the use of a Web-based system with concealment of the trial-group assignment. Eligible and consenting patients were assigned in a 2:1 ratio to receive either the usual standard of care alone or the usual standard of care plus oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days (or until hospital discharge if sooner) or to receive one of the other suitable and available treatments that were being evaluated in the trial. For some patients, dexamethasone was unavailable at the hospital at the time of enrollment or was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from entry in the randomized comparison between dexamethasone and usual care and hence were not included in this report.
The randomly assigned treatment was prescribed by the treating clinician. Patients and local members of the trial staff were aware of the assigned treatments. Procedures A single online follow-up form was to be completed when the patients were discharged or had died or at 28 days after randomization, whichever occurred first. Information was recorded regarding the patientsâ adherence to the assigned treatment, receipt of other trial treatments, duration of admission, receipt of respiratory support (with duration and type), receipt of renal support, and vital status (including the cause of death).
In addition, we obtained routine health care and registry data, including information on vital status (with date and cause of death), discharge from the hospital, and respiratory and renal support therapy. Outcome Measures The primary outcome was all-cause mortality within 28 days after randomization. Further analyses were specified at 6 months. Secondary outcomes were the time until discharge from the hospital and, among patients not receiving invasive mechanical ventilation at the time of randomization, subsequent receipt of invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death.
Other prespecified clinical outcomes included cause-specific mortality, receipt of renal hemodialysis or hemofiltration, major cardiac arrhythmia (recorded in a subgroup), and receipt and duration of ventilation. Statistical Analysis As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned at the start of the erectile dysfunction treatment kamagra. As the trial progressed, the trial steering committee, whose members were unaware of the results of the trial comparisons, determined that if 28-day mortality was 20%, then the enrollment of at least 2000 patients in the dexamethasone group and 4000 in the usual care group would provide a power of at least 90% at a two-sided P value of 0.01 to detect a clinically relevant proportional reduction of 20% (an absolute difference of 4 percentage points) between the two groups. Consequently, on June 8, 2020, the steering committee closed recruitment to the dexamethasone group, since enrollment had exceeded 2000 patients.
For the primary outcome of 28-day mortality, the hazard ratio from Cox regression was used to estimate the mortality rate ratio. Among the few patients (0.1%) who had not been followed for 28 days by the time of the data cutoff on July 6, 2020, data were censored either on that date or on day 29 if the patient had already been discharged. That is, in the absence of any information to the contrary, these patients were assumed to have survived for 28 days. KaplanâMeier survival curves were constructed to show cumulative mortality over the 28-day period.
Cox regression was used to analyze the secondary outcome of hospital discharge within 28 days, with censoring of data on day 29 for patients who had died during hospitalization. For the prespecified composite secondary outcome of invasive mechanical ventilation or death within 28 days (among patients who were not receiving invasive mechanical ventilation at randomization), the precise date of invasive mechanical ventilation was not available, so a log-binomial regression model was used to estimate the risk ratio. Table 1. Table 1.
Characteristics of the Patients at Baseline, According to Treatment Assignment and Level of Respiratory Support. Through the play of chance in the unstratified randomization, the mean age was 1.1 years older among patients in the dexamethasone group than among those in the usual care group (Table 1). To account for this imbalance in an important prognostic factor, estimates of rate ratios were adjusted for the baseline age in three categories (<70 years, 70 to 79 years, and â¥80 years). This adjustment was not specified in the first version of the statistical analysis plan but was added once the imbalance in age became apparent.
Results without age adjustment (corresponding to the first version of the analysis plan) are provided in the Supplementary Appendix. Prespecified analyses of the primary outcome were performed in five subgroups, as defined by characteristics at randomization. Age, sex, level of respiratory support, days since symptom onset, and predicted 28-day mortality risk. (One further prespecified subgroup analysis regarding race will be conducted once the data collection has been completed.) In prespecified subgroups, we estimated rate ratios (or risk ratios in some analyses) and their confidence intervals using regression models that included an interaction term between the treatment assignment and the subgroup of interest.
Chi-square tests for linear trend across the subgroup-specific log estimates were then performed in accordance with the prespecified plan. All P values are two-sided and are shown without adjustment for multiple testing. All analyses were performed according to the intention-to-treat principle. The full database is held by the trial team, which collected the data from trial sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford..
High burden of antibiotic-resistant Mycoplasma genitalium buy kamagra without a prescription in symptomatic urethritisMycoplasma genitalium is an aetiological agent of sexually transmitted urethritis. A cohort study investigated M. Genitalium prevalence, antibiotic resistance buy kamagra without a prescription and association with previous macrolide exposure among 1816 Chinese men who presented with symptomatic urethritis between 2011 and 2015. was diagnosed by PCR, and sequencing was used to detect mutations that confer resistance to macrolides and fluoroquinolones. In 11% of men, M buy kamagra without a prescription.
Genitalium was the sole pathogen identified. Nearly 90% buy kamagra without a prescription of s were resistant to macrolides and fluoroquinolones. Previous macrolide exposure was associated with higher prevalence of resistance (97%). The findings point to the need buy kamagra without a prescription for routine screening for M. Genitalium in symptomatic men with urethritis.
Treatment strategies to overcome buy kamagra without a prescription antibiotic resistance in M. Genitalium are needed.Yang L, Xiaohong S, Wenjing L, et al. Mycoplasma genitalium buy kamagra without a prescription in symptomatic male urethritis. Macrolide use is associated with increased resistance. Clin Infect Dis 2020;5:805â10.
Doi:10.1093/cid/ciz294.A new entry inhibitor offers promise for treatment-experienced patients with multidrug-resistant HIVFostemsavir, the prodrug of temsavir, is an attachment buy kamagra without a prescription inhibitor. By targeting the gp120 protein on the HIV-1 envelope, it prevents viral interaction with the CD4 receptor. No cross-resistance has been described with other antiretroviral agents, including those that buy kamagra without a prescription target viral entry by other modalities. In the phase III BRIGHTE trial, 371 highly treatment-experienced patients who had exhausted â¥4 classes of antiretrovirals received fostemsavir with an optimised regimen. After 48 weeks, 54% of those with 1â2 additional active drugs achieved viral load suppression buy kamagra without a prescription <40 copies/mL.
Response rates were 38% among patients lacking other active agents. Drug-related adverse events buy kamagra without a prescription included nausea (4%) and diarrhoea (3%). As gp120 substitutions reduced fostemsavir susceptibility in up to 70% of patients with virological failure, fostemsavir offers the most valuable salvage option in partnership with other active drugs.Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in adults with buy kamagra without a prescription multidrug-resistant HIV-1 . N Engl J Med 2020;382:1232â43.
Doi. 10.1056/NEJMoa1902493Novel tools to aid identification of hepatitis C in primary careHepatitis C can now be cured with oral antiviral treatment, and improving diagnosis is a key element of elimination strategies.1 A cluster randomised controlled trial in South West England tested performance and cost-effectiveness of an electronic algorithm that identified at-risk patients in primary care according to national recommendations,2 coupled with educational activities and interventions to increase patientsâ awareness. Outcomes were testing uptake, diagnosis and referral to specialist care. Practices in the intervention arm had an increase in all outcome measures, with adjusted risk ratios of 1.59 (1.21â2.08) for uptake, 2.24 (1.47â3.42) for diagnosis and 5.78 (1.60â21.6) for referral. The intervention was highly cost-effective.
Electronic algorithms applied to practice systems could enhance testing and diagnosis of hepatitis C in primary care, contributing to global elimination goals.Roberts K, Macleod J, Metcalfe C, et al. Cost-effectiveness of an intervention to increase uptake of hepatitis C kamagra testing and treatment (HepCATT). Cluster randomised controlled trial in primary care. BMJ 2020;368:m322. Doi:10.1136/bmj.m322Low completion rates for antiretroviral postexposure prophylaxis (PEP) after sexual assaultA 4-week course of triple-agent postexposure prophylaxis (PEP) is recommended following a high-risk sexual assault.3 4 A retrospective study in Barcelona identified 1695 victims attending an emergency room (ER) between 2006 and 2015.
Overall, 883 (52%) started prophylaxis in ER, which was mostly (43%) lopinavir/ritonavir based. Follow-up appointments were arranged for those living in Catalonia (631, 71.5%), and of these, only 183 (29%) completed treatment. Loss to follow-up was more prevalent in those residing outside Barcelona. PEP non-completion was associated with a low perceived risk, previous assaults, a known aggressor and a positive cocaine test. Side effects were common, occurring in up to 65% of those taking lopinavir/ritonavir and accounting for 15% of all discontinuations.
More tolerable PEP regimens, accessible follow-up and provision of 1-month supply may improve completion rates.Inciarte A, Leal L, Masfarre L, et al. Postexposure prophylaxis for HIV in sexual assault victims. HIV Med 2020;21:43â52. Doi:10.1111/hiv.12797.Effective antiretroviral therapy reduces anal high-risk HPV and cancer riskAmong people with HIV, effective antiretroviral therapy (ART) is expected to improve control of anal with high-risk human papillomakamagra (HR-HPV) and reduce the progression of HPV-associated anal lesions. The magnitude of the effect is not well established.
By meta-analysis, people on established ART (vs ART-naive) had a 35% lower prevalence of HR-HPV , and those with undetectable viral load (vs detectable viral load) had a 27% and 16% reduced risk of low and high-grade anal lesions, respectively. Sustained virological suppression on ART reduced by 44% the risk of anal cancer. The role of effective ART in reducing anal HR-HPV and cancer risks is especially salient given current limitations in anal cancer screening, high rates of anal lesion recurrence and access to vaccination.Kelly H, Chikandiwa A, Alemany Vilches L, et al. Association of antiretroviral therapy with anal high-risk human papillomakamagra, anal intraepithelial neoplasia and anal cancer in people living with HIV. A systematic review and meta-analysis.
Lancet HIV. 2020;7:e262â78. Doi:10.1016/S2352-3018(19)30434-5.The impact of sex work laws and stigma on HIV prevention among female sex workersSex work laws and stigma have been established as structural risk factors for HIV acquisition among female sex workers (FSWs). However, individual-level data assessing these relationships are limited. A study examined individual-level data collected in 2011â2018 from 7259 FSWs across 10 sub-Saharan African countries.
An association emerged between HIV prevalence and increasingly punitive and non-protective laws. HIV prevalence among FSWs was 11.6%, 19.6% and 39.4% in contexts where sex work was partly legalised, not recognised or criminalised, respectively. Stigma measures such as fear of seeking health services, mistreatment in healthcare settings, lack of police protection, blackmail and violence were associated with higher HIV prevalence and more punitive settings. Sex work laws that protect sex workers and reduce structural risks are needed.Lyons CE, Schwartz SR, Murray SM, et al. The role of sex work laws and stigmas in increasing HIV risks among sex workers.
Nat Commun 2020;11:773. Doi:10.1038/s41467-020-14593-6.BackgroundCumbria Sexual Health Services (CSHS) in collaboration with Cumbria Public Health and local authorities have established a erectile dysfunction treatment contact tracing pathway for Cumbria. The local system was live 10 days prior to the national system on 18 May 2020. It was designed to interface and dovetail with the governmentâs track and trace programme.Our involvement in this initiative was due to a chance meeting between Professor Matt Phillips, Consultant in Sexual Health and HIV, and the Director of Public Health Cumbria, Colin Cox. Colin knew that Cumbria needed to act fast to prevent the transmission of erectile dysfunction treatment and Matt knew that sexual health had the skills to help.ProcessDespite over 90% of the staff from CSHS being redeployed in March 2020, CSHS maintained urgent sexual healthcare for the county and a phone line for advice and guidance.
As staff began to return to the service in May 2020 we had capacity to spare seven staff members, whose hours were the equivalent of four full-time staff. We had one system administrator, three healthcare assistants, one nurse, Health Advisor Helen Musker and myself.CSHS were paramount to the speed with which the local system began. Following approval from the Trustâs chief executive officer we had adapted our electronic patient records (EPR) system, developed a standard operating procedure and trained staff, using a stepwise competency model, within just 1âday.In collaboration with the local laboratories we developed methods for the input of positive erectile dysfunction treatment results into our EPR derivative. We ensured that labs would be able to cope with the increase in testing and that testing hubs had additional capacity. Testing sites and occupational health were asked to inform patients that if they tested positive they would be contacted by our teams.This initiative involved a multiagency system including local public health (PH) teams, local authority, North Cumbria and Morecambe Bay CCGs, Public Health England (PHE) and the military.
If CSHS recognise more than one positive result in the same area/organisation, they flag this with PH at the daily incident management meeting and environmental health officers (EHOs) provide advice and guidance for the organisation. We have had an active role in the contact tracing for clusters in local general practices, providing essential information to PH to enable them to initiate outbreak control and provide accurate advice to the practices. We are an integral part in recognising cases in large organisations and ensuring prompt action is taken to stem the spread of the disease. The team have provided out-of-hours work to ensure timely and efficient action is taken for all contacts.The local contact tracing pilot has evolved and a database was established by local authorities. Our data fed directly into this from the end of May 2020.
This enables the multiagency team to record data in one place, improving recognition of patterns of transmission.DiscussionCumbria is covered by three National Health Service Trusts, which meant accessing data outside of our Trust was challenging and took more time to establish. There are two CCGs for Cumbria, which meant discussions regarding testing were needed with both North and South CCGs and variations in provision had to be accounted for. There are six boroughs in Cumbria with different teams of EHOs working in each. With so many people involved, not only is there need for large-scale frequent communication across a multisystem team, there is also inevitable duplication of work.Lockdown is easing and sexual health clinics are increasing capacity in a new world of virtual appointments and reduced face-to-face consultations. Staff within the contact tracing team are now balancing their commitments across both teams to maintain their skills and keep abreast of the rapid developments within our service due to erectile dysfunction treatment.
We are currently applying for funding from PH in order to second staff and backfill posts in sexual health.ConclusionCSHS have been able to lend our skills effectively to the local contact tracing efforts. We have expedited the contact tracing in Cumbria and provided crucial information to help contain outbreaks. It has had a positive effect on staff morale within the service and we have gained national recognition for our work. We have developed excellent relationships with our local PH team, PHE, Cumbria Council, EHOs and both CCGs.Cumbria has the infrastructure to meet the demands of a second wave of erectile dysfunction treatment. The beauty of this model is that if we are faced with a second lockdown, sexual health staff will inevitably be available to help with the increased demand for contact tracing.
Our ambition is that this model will be replicated nationally..
High burden of how do i get kamagra antibiotic-resistant Mycoplasma genitalium in symptomatic urethritisMycoplasma genitalium is an aetiological agent of sexually transmitted urethritis. A cohort study investigated M. Genitalium prevalence, antibiotic resistance and association with previous macrolide exposure among 1816 Chinese how do i get kamagra men who presented with symptomatic urethritis between 2011 and 2015.
was diagnosed by PCR, and sequencing was used to detect mutations that confer resistance to macrolides and fluoroquinolones. In 11% of men, M how do i get kamagra. Genitalium was the sole pathogen identified.
Nearly 90% of s were resistant to macrolides and fluoroquinolones how do i get kamagra. Previous macrolide exposure was associated with higher prevalence of resistance (97%). The findings point to the need how do i get kamagra for routine screening for M.
Genitalium in symptomatic men with urethritis. Treatment strategies to overcome antibiotic resistance in M how do i get kamagra. Genitalium are needed.Yang L, Xiaohong S, Wenjing L, et al.
Mycoplasma genitalium in symptomatic how do i get kamagra male urethritis. Macrolide use is associated with increased resistance. Clin Infect Dis 2020;5:805â10.
Doi:10.1093/cid/ciz294.A new entry how do i get kamagra inhibitor offers promise for treatment-experienced patients with multidrug-resistant HIVFostemsavir, the prodrug of temsavir, is an attachment inhibitor. By targeting the gp120 protein on the HIV-1 envelope, it prevents viral interaction with the CD4 receptor. No cross-resistance has been described with other antiretroviral agents, including those that target viral entry how do i get kamagra by other modalities.
In the phase III BRIGHTE trial, 371 highly treatment-experienced patients who had exhausted â¥4 classes of antiretrovirals received fostemsavir with an optimised regimen. After 48 weeks, 54% of those how do i get kamagra with 1â2 additional active drugs achieved viral load suppression <40 copies/mL. Response rates were 38% among patients lacking other active agents.
Drug-related adverse events how do i get kamagra included nausea (4%) and diarrhoea (3%). As gp120 substitutions reduced fostemsavir susceptibility in up to 70% of patients with virological failure, fostemsavir offers the most valuable salvage option in partnership with other active drugs.Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in how do i get kamagra adults with multidrug-resistant HIV-1 .
N Engl J Med 2020;382:1232â43. Doi. 10.1056/NEJMoa1902493Novel tools to aid identification of hepatitis C in primary careHepatitis C can now be cured with oral antiviral treatment, and improving diagnosis is a key element of elimination strategies.1 A cluster randomised controlled trial in South West England tested performance and cost-effectiveness of an electronic algorithm that identified at-risk patients in primary care according to national recommendations,2 coupled with educational activities and interventions to increase patientsâ awareness.
Outcomes were testing uptake, diagnosis and referral to specialist care. Practices in the intervention arm had an increase in all outcome measures, with adjusted risk ratios of 1.59 (1.21â2.08) for uptake, 2.24 (1.47â3.42) for diagnosis and 5.78 (1.60â21.6) for referral. The intervention was highly cost-effective.
Electronic algorithms applied to practice systems could enhance testing and diagnosis of hepatitis C in primary care, contributing to global elimination goals.Roberts K, Macleod J, Metcalfe C, et al. Cost-effectiveness of an intervention to increase uptake of hepatitis C kamagra testing and treatment (HepCATT). Cluster randomised controlled trial in primary care.
BMJ 2020;368:m322. Doi:10.1136/bmj.m322Low completion rates for antiretroviral postexposure prophylaxis (PEP) after sexual assaultA 4-week course of triple-agent postexposure prophylaxis (PEP) is recommended following a high-risk sexual assault.3 4 A retrospective study in Barcelona identified 1695 victims attending an emergency room (ER) between 2006 and 2015. Overall, 883 (52%) started prophylaxis in ER, which was mostly (43%) lopinavir/ritonavir based.
Follow-up appointments were arranged for those living in Catalonia (631, 71.5%), and of these, only 183 (29%) completed treatment. Loss to follow-up was more prevalent in those residing outside Barcelona. PEP non-completion was associated with a low perceived risk, previous assaults, a known aggressor and a positive cocaine test.
Side effects were common, occurring in up to 65% of those taking lopinavir/ritonavir and accounting for 15% of all discontinuations. More tolerable PEP regimens, accessible follow-up and provision of 1-month supply may improve completion rates.Inciarte A, Leal L, Masfarre L, et al. Postexposure prophylaxis for HIV in sexual assault victims.
HIV Med 2020;21:43â52. Doi:10.1111/hiv.12797.Effective antiretroviral therapy reduces anal high-risk HPV and cancer riskAmong people with HIV, effective antiretroviral therapy (ART) is expected to improve control of anal with high-risk human papillomakamagra (HR-HPV) and reduce the progression of HPV-associated anal lesions. The magnitude of the effect is not well established.
By meta-analysis, people on established ART (vs ART-naive) had a 35% lower prevalence of HR-HPV , and those with undetectable viral load (vs detectable viral load) had a 27% and 16% reduced risk of low and high-grade anal lesions, respectively. Sustained virological suppression on ART reduced by 44% the risk of anal cancer. The role of effective ART in reducing anal HR-HPV and cancer risks is especially salient given current limitations in anal cancer screening, high rates of anal lesion recurrence and access to vaccination.Kelly H, Chikandiwa A, Alemany Vilches L, et al.
Association of antiretroviral therapy with anal high-risk human papillomakamagra, anal intraepithelial neoplasia and anal cancer in people living with HIV. A systematic review and meta-analysis. Lancet HIV.
2020;7:e262â78. Doi:10.1016/S2352-3018(19)30434-5.The impact of sex work laws and stigma on HIV prevention among female sex workersSex work laws and stigma have been established as structural risk factors for HIV acquisition among female sex workers (FSWs). However, individual-level data assessing these relationships are limited.
A study examined individual-level data collected in 2011â2018 from 7259 FSWs across 10 sub-Saharan African countries. An association emerged between HIV prevalence and increasingly punitive and non-protective laws. HIV prevalence among FSWs was 11.6%, 19.6% and 39.4% in contexts where sex work was partly legalised, not recognised or criminalised, respectively.
Stigma measures such as fear of seeking health services, mistreatment in healthcare settings, lack of police protection, blackmail and violence were associated with higher HIV prevalence and more punitive settings. Sex work laws that protect sex workers and reduce structural risks are needed.Lyons CE, Schwartz SR, Murray SM, et al. The role of sex work laws and stigmas in increasing HIV risks among sex workers.
Nat Commun 2020;11:773. Doi:10.1038/s41467-020-14593-6.BackgroundCumbria Sexual Health Services (CSHS) in collaboration with Cumbria Public Health and local authorities have established a erectile dysfunction treatment contact tracing pathway for Cumbria. The local system was live 10 days prior to the national system on 18 May 2020.
It was designed to interface and dovetail with the governmentâs track and trace programme.Our involvement in this initiative was due to a chance meeting between Professor Matt Phillips, Consultant in Sexual Health and HIV, and the Director of Public Health Cumbria, Colin Cox. Colin knew that Cumbria needed to act fast to prevent the transmission of erectile dysfunction treatment and Matt knew that sexual health had the skills to help.ProcessDespite over 90% of the staff from CSHS being redeployed in March 2020, CSHS maintained urgent sexual healthcare for the county and a phone line for advice and guidance. As staff began to return to the service in May 2020 we had capacity to spare seven staff members, whose hours were the equivalent of four full-time staff.
We had one system administrator, three healthcare assistants, one nurse, Health Advisor Helen Musker and myself.CSHS were paramount to the speed with which the local system began. Following approval from the Trustâs chief executive officer we had adapted our electronic patient records (EPR) system, developed a standard operating procedure and trained staff, using a stepwise competency model, within just 1âday.In collaboration with the local laboratories we developed methods for the input of positive erectile dysfunction treatment results into our EPR derivative. We ensured that labs would be able to cope with the increase in testing and that testing hubs had additional capacity.
Testing sites and occupational health were asked to inform patients that if they tested positive they would be contacted by our teams.This initiative involved a multiagency system including local public health (PH) teams, local authority, North Cumbria and Morecambe Bay CCGs, Public Health England (PHE) and the military. If CSHS recognise more than one positive result in the same area/organisation, they flag this with PH at the daily incident management meeting and environmental health officers (EHOs) provide advice and guidance for the organisation. We have had an active role in the contact tracing for clusters in local general practices, providing essential information to PH to enable them to initiate outbreak control and provide accurate advice to the practices.
We are an integral part in recognising cases in large organisations and ensuring prompt action is taken to stem the spread of the disease. The team have provided out-of-hours work to ensure timely and efficient action is taken for all contacts.The local contact tracing pilot has evolved and a database was established by local authorities. Our data fed directly into this from the end of May 2020.
This enables the multiagency team to record data in one place, improving recognition of patterns of transmission.DiscussionCumbria is covered by three National Health Service Trusts, which meant accessing data outside of our Trust was challenging and took more time to establish. There are two CCGs for Cumbria, which meant discussions regarding testing were needed with both North and South CCGs and variations in provision had to be accounted for. There are six boroughs in Cumbria with different teams of EHOs working in each.
With so many people involved, not only is there need for large-scale frequent communication across a multisystem team, there is also inevitable duplication of work.Lockdown is easing and sexual health clinics are increasing capacity in a new world of virtual appointments and reduced face-to-face consultations. Staff within the contact tracing team are now balancing their commitments across both teams to maintain their skills and keep abreast of the rapid developments within our service due to erectile dysfunction treatment. We are currently applying for funding from PH in order to second staff and backfill posts in sexual health.ConclusionCSHS have been able to lend our skills effectively to the local contact tracing efforts.
We have expedited the contact tracing in Cumbria and provided crucial information to help contain outbreaks. It has had a positive effect on staff morale within the service and we have gained national recognition for our work. We have developed excellent relationships with our local PH team, PHE, Cumbria Council, EHOs and both CCGs.Cumbria has the infrastructure to meet the demands of a second wave of erectile dysfunction treatment.
The beauty of this model is that if we are faced with a second lockdown, sexual health staff will inevitably be available to help with the increased demand for contact tracing. Our ambition is that this model will be replicated nationally..
Justice, one buy kamagra online without prescription of the four Beauchamp and Childress prima facie basic principles of biomedical ethics, is explored http://old.brittfirearms.com/?page_id=2 in two excellent papers in the current issue of the journal. The papers stem from a British Medical Association (BMA) essay competition on justice and fairness in medical practice and policy. Although the competition was open to (almost) all comers, of the 235 entries both the winning paper by Alistair Wardrope1 and the highly commended runner-up by Zoe Fritz and buy kamagra online without prescription CaitrÃona Cox2 were written by practising doctorsâa welcome indication of the growing importance being accorded to philosophical reflection about medical practice and practices within medicine itself. Both papers are thoroughly thought provoking and represent two very different approaches to the topic. Each deserves a careful read.The competition was a component of a BMA 2019/2020 âPresidential projectâ on fairness and justice and asked candidates to âuse ethical reasoning and theory to tackle challenging, practical, contemporary, problems in health care and help provide a solution based on an explained and defended sense of fairness/justiceâ.In this guest editorial Iâd like to explain why, in 2018 on becoming president-elect of the BMA, I chose the theme of justice and fairness in medical ethics for my 2019â2020 Presidential projectâand why in a world of massive and ever-increasing and remediable health inequalities biomedical ethics requires greater international and interdisciplinary efforts to try to reach agreement on the need to achieve greater âhealth justiceâ and to reach agreement on what that commitment actually means and on what in practice it requires.First, some background.
As president I buy kamagra online without prescription was offered the wonderful opportunity to pursue, with the organisationâs formidable assistance, a âprojectâ consistent with the BMAâs interests and values. As a hybrid of general medical practitioner and philosopher/medical ethicist, and as a firm defender of the Beauchamp and Childress four principles approach to medical ethics,3 I chose to try to raise the ethical profile of justice and fairness within medical ethics.My first objective was to ask the BMA to ask the World Medical Association (WMA) to add an explicit commitment âto strive to practise fairly and justly throughout my professional lifeâ to its contemporary version of the Hippocratic Oathâthe Declaration of Geneva4âand to the companion document the International Code of Medical Ethics.5 The stimulus for this proposal was the WMAâs addition in 2017 of the principle of respect for patientsâ autonomy. Important as that buy kamagra online without prescription addition is, it is widely perceived (though in my own view mistakenly) as being too much focused on individual patients and not enough on communities, groups and populations. The simple addition of a commitment to fairness and justice would provide a âbalancingâ moral commitment.Adding the fourth principleIt would also explicitly add the fourth of those four prima facie moral commitments, increasingly widely accepted by doctors internationally. Two of themâbenefiting our patients (beneficence) and doing so with as little harm as possible (non-maleficence)âhave been an integral part of medical ethics since Hippocratic times.
Respect for buy kamagra online without prescription autonomy and justice are very much more recent additions to medical ethics. The WMA, having added respect for autonomy to the Declaration of Geneva, should, I proposed, complete the quartet by adding the âbalancingâ principle of fairness and justice.Since the Declaration is unlikely to be revised for several years, it seems likely that the proposal to add to it an explicit commitment to practise fairly and justly will have to wait. However, an explicit commitment to justice and fairness has, at the BMAâs request, been added to the draft of the International Code of Medical Ethics and it seems reasonable to buy kamagra online without prescription hope and expect that it will remain in the final document.Adding a commitment to fairness and justice is the easy part!. Few doctors would on reflection deny that they ought to try to practise fairly and justly. It is far more difficult to say what is actually meant by this.
Two additional components of my Presidential projectâthe essay competition and a conference (which with luck will have been held, virtually, shortly before publication of this editorial)âsought to help elucidate just what is meant by practising fairly and justly.One of the most striking features of the essay competition was the readiness of many writers to point to injustices in the context of medical practice and policy and describe ways of remedying them, but without giving a specific buy kamagra online without prescription account of justice and fairness on the basis of which the diagnosis of injustice was made and the remedy offered.Wardropeâs winning essay comes close to such an approach by challenging the implied premise that an account of justice and fairness must provide some such formal theory. In preference, he points to the evident injustice and unsustainability of humansâ degradation of âthe Landâ and its atmosphere and its inhabitants and then challenges some assumptions of contemporary philosophy and ethics, especially what he sees as their anthropocentric and individualistic focus. Instead, he invokes Leopold Aldoâs âLand Ethicâ (as well as buy kamagra online without prescription drawing in aid Isabelle Stengerâs focus on âthe intrusion of Gaiaâ). In his thoughtful and challenging paper, he seeks to refocus our ethicsâincluding our medical ethics and our sense of justice and fairnessâon mankindâs exploitative threat, during this contemporary âanthropoceneâ stage of evolution, to the continuing existence of humans and of all forms of life in our âbiotic communityâ. As remedy, the author, allying his approach to those of contemporary virtue ethics, recommends the beneficial outcomes that would be brought about by a sense of fairness and justiceâa developed and sensitive âecological conscienceâ as he calls itâthat embraces the interests of the entire biotic community of which we humans are but a part.Fritz and Cox pursue a very different and philosophically more conventional approach to the essay competitionâs question and offer a combination and development of two established philosophical theories, those of John Rawls and Thomas Scanlon, to provide a philosophically robust and practically beneficial methodology for justice and fairness in medical practice and policy.
Briefly summarised, they recommend a two-stage approach for healthcare buy kamagra online without prescription justice. First, those faced with a problem of fairness or justice in healthcare or policy should use Thomas Scanlonâs proposed contractualist approach whereby reasonable people seek solutions that they and others could not âreasonably rejectâ. This stage would involve committees of decision-makers and representatives of relevant stakeholders looking at the immediate and longer term impact on existing stakeholders of proposed solutions. They would then check those solutions against substantive criteria of justice derived from Rawlsâ theory (which, via his theoretical device of the âveil of ignoranceâ, Rawls and the buy kamagra online without prescription authors argue that all reasonable people can be expected to accept!. ).
The Rawlsian criteria relied on buy kamagra online without prescription by Fritz and Cox are equity of access to healthcare. The âdifference principleâ whereby avoidable inequalities of primary goods can only be justified if they benefit the most disadvantaged. The just savings principle, of particular importance for ensuring intergenerational justice and sustainability. And a criterion of increased openness, transparency and accountability.It would of buy kamagra online without prescription course be naïve to expect a single universalisable solution to the question âwhat do we mean by fairness and justice in health care?.  As the papers by Wardrope1 and Fritz and Cox2 demonstrate, there can be very wide differences of approach in well-defended accounts.
My own hope for buy kamagra online without prescription my project is to emphasise the importance first of committing ourselves within medicine to practising fairly and justly in whatever branch we practise. And then to think carefully about what we do mean by that and act accordingly.Following AristotleFor my own part, over 40 years of looking, I have not yet found a single substantive theory of justice that is plausibly universalisable and have had to content myself with Aristotleâs formal, almost content-free but probably universalisable theory, according to which equals should be treated equally and unequals unequally in proportion to the relevant inequalitiesâwhat some health economists refer to as horizontal and vertical justice or equity.6Beauchamp and Childress in their recent eighth and âperhaps finalâ edition of their foundational âPrinciples of biomedical ethicsâ1 acknowledge that â[t]he construction of a unified theory of justice that captures our diverse conceptions and principles of justice in biomedical ethics continues to be controversial and difficult to pin downâ.They still cite Aristotleâs formal principle (though with less explanation than in their first edition back in 1979) and they still believe that this formal principle requires substantive or âmaterialâ content if it is to be useful in practice. They then describe six different theories of justiceâfour âtraditionalâ (utilitarian, libertarian, communitarian and egalitarian) and two newer theories, which they suggest may be more helpful in the context of health justice, one based on capabilities and the other on actual well-being.They again end their discussion of justice with their reminder that âPolicies of just access to health care, strategies of efficiencies in health care institutions, and global needs for the reduction of health-impairing conditions dwarf in social importance every other issue considered in this bookâ â¦â¦. Âevery society must ration buy kamagra online without prescription its resources but many societies can close gaps in fair rationing more conscientiously than they have to dateâ [emphasis added]. And they go on to stress their own support for ârecognition of global rights to health and enforceable rights to health care in nation-statesâ.For my own part I recommend, perhaps less ambitiously, that across the globe we extract from Aristotleâs formal theory of justice a starting point that ethically requires us to focus on equality and always to treat others as equals and treat them equally unless there are moral justifications for not doing so.
Where such justifications exist we should say what they are, explain the moral assumptions that justify them and, to the extent possible, seek the agreement of those affected.IntroductionIt did not occur to the Governor that there might be more than one definition of what is good ⦠It did not occur to him that while the courts were writing one definition of goodness in the buy kamagra online without prescription law books, fires were writing quite another one on the face of the land. (Leopold, âGood Oakâ1, pp 10â11)As I wrote the abstract that would become this essay, wildfires were spreading across Australiaâs east coast. By the time I was invited to write the essay, back-to-back winter storms were flooding communities all around my home. The essay has buy kamagra online without prescription been written in moments of respite between shifts during the erectile dysfunction treatment kamagra. Every one of these events was described as âunprecedentedâ.
Yet each is becoming increasingly likely, and that due to our interactions with our environment.Public discourse surrounding these events is dominated by questions of justice and fairness. How to balance competing imperatives of protecting individual lives against risk of spreading buy kamagra online without prescription contagion. How best to allocate scarce resources like intensive care beds or mechanical ventilators. The conceptual tools of clinical ethics buy kamagra online without prescription are well tailored to these sorts of questions. The rights of the individual versus the community, issues of distributive justiceâthese are familiar to anyone with even a passing acquaintance with its canonical debates.What biomedical ethics has remained largely silent on is how we have been left to confront these decisions.
How human activity has eroded Earthâs life support systems to make the âunprecedentedâ the new normal. A medical ethic buy kamagra online without prescription fit for the Anthropoceneâour (still tentative) geological epoch defined by human influence on natural systemsâmust be able not just to react to the consequences of our exploitation of the natural world, but reimagine our relationship with it.Those reimaginations already exist, if we know where to look for them. The âLand Ethicâ of the US conservationist Aldo Leopold offers one such vision.i Developed over decades of experience working in and teaching land management, the Land Ethic is most famously formulated in an essay of the same name published shortly before Leopoldâs death fighting a wildfire on a neighbourâs farm. It begins with a reinterpretation of the buy kamagra online without prescription ethical relationship between humanity and the âland communityâ, the ecosystems we live within and depend upon. Moving us from âconquerorâ to âplain member and citizenâ of that community1 (p 204).
Land ceases to be a resource to be exploited for human need once we view ourselves as part of, and only existing within, the land community. Our moral buy kamagra online without prescription evaluations shift consonantly:A thing is right when it tends to preserve the integrity, stability, and beauty of the biotic community. It is wrong when it tends otherwise.1 (pp 224â225)The justice of the Land Ethic questions many presuppositions of biomedical ethics. By valuing the community in itselfâin buy kamagra online without prescription a way irreducible to the welfare of its membersâit steps away from the individualism axiomatic in contemporary bioethics.2 Viewing ourselves as citizens of the land community also extends the moral horizons of healthcare from a solely human focus, taking seriously the interests of the non-human members of that community. Taking into account the âstabilityâ of the community requires intergenerational justiceâthat we consider those affected by our actions now, and their implications for future generations.3 The resulting vision of justice in healthcareâone that takes climate and environmental justice seriouslyâcould offer health workers an ethic fit for the future, demonstrating ways in which practice must change to do justice to patients, public and planetânow and in years to come.Healthcare in the AnthropoceneSeemeth it a small thing unto you to have fed upon good pasture, but ye must tread down with your feet the residue of your pasture?.
And to have drunk of the clear waters, but ye must foul the residue with your feet?. (Ezekiel 34:18, quoted in Leopold, âConservation in the Southwestâ4, p 94)The majority of the development of human societies worldwideâincluding all of recorded human historyâhas taken place within a single geological epoch, a roughly 11â600 yearlong period of buy kamagra online without prescription relative warmth and climatic stability known as the Holocene. That stability, however, can no longer be taken for granted. The epoch that has sustained most of human development is giving way to one shaped by the planetary consequences of that developmentâthe Anthropocene.The Anthropocene is marked by accelerating degradation of the ecosystems that have sustained human societies. Human activity is already estimated to have raised global temperatures 1°C above preindustrial levels, and if emissions continue at current levels we are likely to reach 1.5°C between 2030 and 2052.5 The global rate of species extinction is orders of magnitude higher than the average over the past 10 million years.6 Ocean acidification, deforestation and disruption of nitrogen and phosphorus flows are likely at or beyond sustainable planetary boundaries.7Yet this period has also seen rapid (if uneven) improvements in human health, with improved life expectancy, buy kamagra online without prescription falling child mortality and falling numbers of people living in extreme poverty.
The 2015 report of the Rockefeller Foundation-Lancet Commission on planetary health explained this dissonance in stark terms. Âwe have been mortgaging the health of future generations to realise buy kamagra online without prescription economic and development gains in the present.â7In the instrumental rationality of modernity, nature has featured only as inexhaustible resource and infinite sink to fuel social and economic ends. But this disenchanted worldview can no longer hide from the implausibility of these assumptions. It cannot resist what the philosopher Isabelle Stengers has called âthe intrusion of Gaiaâ.8 The present kamagraâmade more likely by deforestation, land use change and biodiversity loss9âis just the most immediately salient of these intrusions. Anthropogenic environmental changes are increasing buy kamagra online without prescription undernutrition, increasing range and transmissibility of many vectorborne and waterborne diseases like dengue fever and cholera, increasing frequency and severity of extreme weather events like heatwaves and wildfires, and driving population exposure to air pollutionâwhich already accounts for over 7 million deaths annually.10These intrusions will shape healthcare in the Anthropocene.
This is because health workers will have to deal with their consequences, and because modern industrialised healthcare as practised in most high-income countriesâand considered aspirational elsewhereâwas borne of the same worldview that has mortgaged the health of future generations. The health sector in the USA is estimated to account buy kamagra online without prescription for 8% of the countryâs greenhouse gas footprint.11 Pharmaceutical production and waste causes more local environmental degradation, accumulating in water supplies with damaging effects for local flora and fauna.12 Public health has similarly embraced short-term gains with neglect of long-term consequences. Health messaging was instrumental to the development and popularisation of many disposable and single-use products, while a 1947 report funded by the Rockefeller Foundation (who would later fund the landmark 2015 Lancet report on planetary health) popularised the high-meat, high-dairy âAmericanâ dietâdependent on fossil fuel-driven intensive agricultural practicesâas the healthy ideal.13Healthcare fit for the Anthropocene requires a shift in perspectives that allows us to see and work with the intrusion of Gaia. But can dominant approaches in bioethics incorporate that shift?. A perfect moral stormWe have built a beautiful piece of social machinery buy kamagra online without prescription ⦠which is coughing along on two cylinders because we have been too timid, and too anxious for quick success, to tell the farmer the true magnitude of his obligations.
(Leopold, âThe Ecological Conscienceâ4, p 341)At local, national and international scales, the lifestyles of the wealthiest pose an existential threat to the poorest and most marginalised in society. Our actions now buy kamagra online without prescription are depriving future generations of the environmental prerequisites of good health and social flourishing. If justice means, as Ranaan Gillon parses it, âthe moral obligation to act on the basis of fair adjudication between competing claimsâ,14 then this state of affairs certainly seems unjust. However, the tools available for grappling with questions of justice in bioethics seem ill equipped to deal with these sorts of injustice.To illustrate this problem, consider how Gillon further fleshes out his description of justice. In terms of fair distribution of buy kamagra online without prescription scarce resources, respect for peopleâs rights, and respect for morally acceptable laws.
The first of theseâlabelled distributive justiceâconcerns how fairly to allot finite resources among potential beneficiaries. Classic problems of distributive justice in healthcare concern a group of people at a particular time (usually patients), who could each benefit from a particular resource (historically, discussions have often focused on transplant organs. More recently, intensive care beds buy kamagra online without prescription and ventilators have come to the fore). But there are fewer of these resources than there are people with a need for them. Such discussions are not easy, but they are at least familiarâwe know where to begin with buy kamagra online without prescription them.
We can consider each partyâs need, their potential to benefit from the resource, any special rights or other claims they may have to it, and so forth. The distribution of benefits and harms in the Anthropocene, however, does not comfortably fit this formalism. It is one thing to say that there is but one intensive care bed, from which Smith buy kamagra online without prescription has a good chance of gaining another year of life, Jones a poor chance, and so offer it to Smith. Another entirely to say that production of the materials consumed in Smithâs care has contributed to the degradation of scarce water supplies on the other side of the globe, or that the unsustainable pattern of energy use will affect innumerable other future persons in poorly quantifiable ways through fuelling climate change. The calculations of distributive justice are well suited buy kamagra online without prescription to problems where there are a set pool of potential beneficiaries, and the use of the scarce resources available affects only those within that pool.
But global environmental problems do not fit this patternâthe effects of our actions are spatially and temporally dispersed, so that large numbers of present and future people are affected in different ways.Nor can this problem be readily addressed by turning to Gillonâs second category of obligations of justice, those grounded in human rights. For while it might be plausible (if not entirely uncontroversial) to say that those communities whose water supplies are degraded by pharmaceutical production have a right to clean water, it is another thing entirely to say that Smithâs healthcare is directly violating that right. It would not be true to say that, were it not for the resources used in caring for Smith, that the communities in question would face no threat buy kamagra online without prescription to water securityâindeed, they would likely make no appreciable difference. Similarly for the effects of Smithâs care on future generations facing accelerating environmental change.iiThe issue here is of fragmentation of agency. While it is not the case that Smithâs care is directly responsible for these environmental harms, buy kamagra online without prescription the cumulative consequences of many such actsâand the ways in which these acts are embedded in particular systems of energy generation, waste management, international trade, and so onâare reliably producing these harms.
The injustice is structural, in Iris Marion Youngâs terminologyâarising from the ways in which social structures constrain individuals from pursuing certain courses of action, and enable them to follow others, with side effects that cumulatively produce devastating impacts.15Gillon describes the third component of justice as respect for morally acceptable laws. But there is little reason to believe that existing legal frameworks provide sufficient guidance to address these structural injustices. While the intricacies of global governance are well beyond what I can hope to address here, the stark fact remains that, despite the international commitment of the 2015 Paris Agreement to attempt to keep global temperature rise to 1.5°C above buy kamagra online without prescription preindustrial levels, the Intergovernmental Panel on Climate Change estimates that present national commitmentsâeven if these are substantially increased in coming yearsâwill take us well beyond that target.5 kamagra tablet online Confronted by such institutional inadequacy, respect for the rule of law is inadequate to remedy injustice.The confluence of these particular featuresâdispersion of causes and effects, fragmentation of agency and institutional inadequacyâmakes it difficult for us to reason ethically about the choices we have to make. Stephen Gardiner calls this a âperfect moral stormâ.16 Each of these factors individually would be difficult to address using the resources of contemporary biomedical ethics. Their convergence makes it seem insurmountable.This perfect storm was not, however, unpredictable.
Van Rensselaer Potter, buy kamagra online without prescription a professor of Oncology responsible for introducing the term âbioethicsâ into Anglophone discourse, observed that since he coined the phrase, the study of bioethics had diverged from his original usage (governing all issues at the intersection of ethics and the biological sciences) to a narrow focus on the moral dilemmas arising in interactions between individuals in biomedical contexts. Potter predicted that the short-term, individualistic and medicalised focus of this approach would result in a neglect of population-level and ecological-level issues affecting human and planetary health, with catastrophic consequences.17 His proposed solution was a new âglobal bioethicsâ, grounded in a new understanding of humanityâs position within planetary systemsâone articulated by the Land Ethic.The Land EthicA land ethic changes the role of Homo sapiens from conqueror of the land-community to plain member and citizen of it. It implies respect for his fellow-members, and also respect for the community as such.iii (Leopold, âThe Land Ethicâ1, p 204)Developed throughout a career buy kamagra online without prescription in forestry, conservation and wildlife management, the Land Ethic is less an attempt to provide a set of maxims for moral action, than to shift our perspectives of the moral landscape. In his working life, Aldo Leopold witnessed how actions intended to optimise short-term economic outcomes eroded the environments on which we dependâwhether soil degradation arising from intensive farming and deforestation, or disruption of freshwater ecosystems by industrial dairy farming. He also saw that contemporary morality remained silent on such actions, even when their consequences were to the collective detriment of all.Leopold argued that a series of âhistorical accidentsâ left our morality particularly ill suited to handle these intrusions of Gaiaâwith a worldview that considered them âintrusionsâ, rather than the predictable response of our biotic community.
These âaccidentsâ buy kamagra online without prescription were. The unusual resilience of European ecological communities to anthropogenic interference (England survived an almost wholesale deforestation without consequent loss of ecosystem resilience, while similar changes elsewhere resulted in permanent environmental degradation). And the legacy of European settler colonialism, meaning that an ethic buy kamagra online without prescription arising in these particular conditions came to dominate global social arrangements4 (p 311). The first of these supported a worldview in which âLand ⦠is ⦠something to be tamed rather than something to be understood, loved, and lived with. Resources are still regarded as separate entities, indeed, as commodities, rather than as our cohabitants in the land communityâ4 (p 311).
The second enabled the marginalisation buy kamagra online without prescription of other views. In this genealogy, Leopold anticipated the perfect moral storm discussed above. His intent with the Land Ethic was to navigate it.There are three key components of the Land Ethic that buy kamagra online without prescription comprise the first three sections of Leopoldâs final essay on the subject. (1) the âcommunity conceptâ that allows communities as wholes to have intrinsic value. (2) the âethical sequenceâ that situates the value of such communities as extending, not replacing, values assigned to individuals.
And (3) the âecological conscienceâ that views ethical action not in terms of following a particular code, but in developing appropriate moral perception.The community conceptThe most widely quoted passage of Leopoldâs buy kamagra online without prescription opusâalready cited above, and frequently (mis)taken as a summary maxim of the ethicâstates that:A thing is right when it tends to preserve the integrity, stability, and beauty of the biotic community. It is wrong when it tends otherwise.1 (pp 224â225)This passage makes the primary object of our moral responsibilities âthe biotic communityâ, a term Leopold uses interchangeably with the âland communityâ. Leopoldâs community concept is notable in at least three respects. Its holismâan embrace of the moral significance of communities in a way that is not simply reducible to the significance of buy kamagra online without prescription its individual members. Its understanding of communities as temporally extended, placing importance on their âintegrityâ and âstabilityâ.
And its rejection of anthropocentrism, affording humanity a place as âplain member and citizenâ of a broader land community.Individualism is so prevalent in biomedical buy kamagra online without prescription ethics that it is scarcely argued for, instead forming part of the âbackground constellation of valuesâ2 tacitly assumed within the field. We are used to evaluating the well-being of a community as a function of the well-being of its individual membersâthis is the rationale underlying quality-adjusted life year calculations endemic within health economics, and most discussions of distributive justice adopt some variation of this approach. Holism instead proposes that this makes no more sense than evaluating a personâs well-being as an aggregate of the well-being of their individual organs. While we can sensibly talk about peopleâs hearts, livers or kidneys, their health is defined in terms of and constitutively dependent on the health of the person as a whole buy kamagra online without prescription. Similarly, holism proposes, while individuals can be identified separately, it only makes sense to talk about them and their well-being in the context of the larger biotic community which supports and defines us.Holism helps us to negotiate the issues that confront individualistic accounts of collective well-being in Anthropocene health injustices.
In the previous section, we found in the environmental consequences of industrialised healthcare that it is difficult to identify which parties in particular are harmed, and how much each individual action contributes buy kamagra online without prescription to those harms. But our intuition that the overall result is unfair or unjust is itself a holistic assessment of the overall outcome, not dependent on our calculation of the welfare of every party involved. Holism respects the intuition that saysâno matter the individuals involvedâa world where people now exploit ecological resources in a fashion that deprives people in the future of the prerequisites of survival, is worse than one where communities now and in the future live in a sustainable relationship with their environment.The second aspect of Leopoldâs community concept is that the community is something that does not exist at a single time and placeâit is defined in terms of its development through time. Promoting the buy kamagra online without prescription âintegrityâ and âstabilityâ of the community requires that we not just consider its immediate interests, but how that will affect its long-term sustainability or resilience. We saw earlier the difficulties in trying to say just who is harmed and how when we approach harm to future generations individualistically.
But from the perspective of the Land Ethic, when we exploit environmental resources in ways that will have predictable damaging results for future generations, the object of our harm is not just some purely notional buy kamagra online without prescription future person. It is a presently existing, temporally extended entityâthe community of which they will be part.Lastly, Leopoldâs community is quite consciously a bioticânot merely humanâcommunity. Leopold defines the land community as the open network of energy and mineral exchange that sustains all aspects of that network:Land⦠is not merely soil. It is a fountain of energy flowing through a circuit of soils, plants, and animals buy kamagra online without prescription. Food chains are the living channels which conduct energy upward.
Death and decay return it to the soil. The circuit is buy kamagra online without prescription not closed. Some energy is dissipated in decay, some is added by absorption, some is stored in soils, peats, and forests, but it is a sustained circuit, like a slowly augmented revolving fund of life.4 (pp 268â269)While the components within this network may change, the land community as a whole remains stable when the overall complexity of the network is not disruptedâother components are able to adjust to these changes, or new ones arise to take their place.ivThe normative inference Leopold makes from his understanding of the land community is this. It makes no sense to single out individual entities within the community as being especially valuable or useful, without taking into account buy kamagra online without prescription the whole community upon which they mutually depend. To do so is self-defeating.
By privileging the interests of a few members of the community, we ultimately undermine the prerequisites of their existence.The ethical sequenceThe Land Ethicâs holism is in fact its most frequently critiqued feature. Its emphasis on the value of the biotic community leads some to allege a subjugation of individual interests to buy kamagra online without prescription the needs of the environment. This critique neglects how Leopold positions the Land Ethic in what he calls the âethical sequenceâ. This is the gradual extension of scope of ethical considerations, both in terms of the complexity of social interactions they cover (from interactions between two people, to the structure of progressively larger social groups), and in the kinds of person they acknowledge buy kamagra online without prescription as worthy of moral consideration (as we resist, for example, classist, sexist or racist exclusions from personhood).This sequence serves less as a description of the history of morality, than a prescription for how we should understand the Land Ethic as adding to, rather than supplanting, our responsibilities to others. We do not argue that taking seriously health workersâ responsibilities for public health and health promotion supplants their duties to the patients they work with on a daily basis.
Similarly, the Land Ethic implies ârespect for [our] fellow members, and also respect for the community as suchâ1 (p 204). At times, buy kamagra online without prescription our responsibilities towards these different parties may come into tension. But balancing these responsibilities has always been part of the work of clinical ethics.The ecological conscienceIf the community concept gives a definition of the good, and the ethical sequence situates this definition within the existing moral landscape, neither offers an explicit decision procedure to guide right action. In arguing for the âecological conscienceâ, Leopold explains his rationale for not attempting to articulate such buy kamagra online without prescription a procedure. In his career as conservationist, Leopold witnessed time and again laws nominally introduced in the name of environmental protection that did little to achieve their long-term goals, while exacerbating other environmental threats.v This is not surprising, given the âperfect moral stormâ of Anthropocene global health and environmental threats discussed above.
The cumulative results of apparently innocent actions can be widespread and damaging.Leopoldâs response to this problem is to advocate the cultivation of an âecological conscienceâ. What is needed to promote a healthy human relationship with the land community is not for us to be told exactly how and how not to act in the face of environmental health threats, but rather to buy kamagra online without prescription shift our view of the land from âa commodity belonging to usâ towards âa community to which we belongâ1 (p viii). To understand what the Land Ethic requires of us, therefore, we should learn more about the land community and our relationship with it, to develop our moral perception and extend its scope to embrace the non-human members of our community.Seen in this light, the Land Ethic shares much in common with virtue ethics, where right action is defined in terms of what the moral agent would do, rather than vice versa. But rather than the Eudaimonia of individual human flourishing proposed by Aristotle, the phronimos of the Land Ethic sees their telos coming from their position within the land community. While clinical virtue ethicists have traditionally taken the virtues of medical practice to be grounded in the interaction with individual patients, the realities buy kamagra online without prescription of healthcare in the Anthropocene mean that limiting our moral perceptions in this way would ultimately be self-defeatingâhurting those very patients we mean to serve (and many more besides).18 The virtuous clinician must adopt a view of the moral world that can focus on a person both as an individual, and simultaneously as member of the land community.
I will close by exploring how adopting that perspective might change our practice.Justice in the AnthropoceneFailing this, it seems to me we fail in the ultimate test of our vaunted superiorityâthe self-control of environment. We fall buy kamagra online without prescription back into the biological category of the potato bug which exterminated the potato, and thereby exterminated itself. (Leopold, âThe River of the Mother of Godâ4, p 127)I have articulated some of the challenges healthcare faces in the Anthropocene. I have suggested that the tools presently available to clinical ethics may be inadequate to meet them. The Land Ethic invites us to reimagine our position in and relationship with the land community buy kamagra online without prescription.
I want to close by suggesting how the development of an ecological conscience might support a transition to more just healthcare. I will not endeavour to give detailed prescriptions for action, given Leopoldâs warnings buy kamagra online without prescription about the limitations of such codifications. Rather, I will attempt to show how the cultivation of an ecological conscience might change our perception of what justice demands. Following the tradition of virtue ethics with which the Land Ethic holds much in common, this is best achieved by looking at models of virtuous action, and exploring what makes it virtuous.19Industrialised healthcare developed within a paradigm that saw the environment as inert resource and held that the scope of clinical ethics ranged only over the clinicianâs interaction with their patients. When we begin to see clinician and patient not as standing apart from the environment, but as âmember and citizen of the land communityâ, their relationship with one another and with the world around them buy kamagra online without prescription changes consonantly.
The present kamagra has only begun to make commonplace the idea that health workers do not simply treat infectious diseases, but interact with them in a range of ways, including as vectorâand as a result our moral obligations in confronting them may extend beyond the immediate clinical encounter, to cover all the other ways we may contract or spread disease. But we may be responsible for disease outbreaks with buy kamagra online without prescription conditions other than erectile dysfunction treatment, and in ways beyond simply becoming infected. The development of an ecological conscience would show how our practices of consumption may fuel deforestation that accelerates the emergence of novel pathogens, or support intensive animal rearing that drives antibiotic resistance.18The Land Ethic also challenges us not to abstract our work away from the places in which it takes place. General practitioner surgeries and hospitals are situated within social and land communities alike, shaping and shaped by them. These spaces can be used in ways that support or undermine those buy kamagra online without prescription communities.
Surgeries can work to empower their communities to pursue more sustainable and healthy diets by doubling as food cooperatives, or providing resources and âsocial prescriptionsâ for increased walking and cycling. Hospitals can use their extensive real estate to provide publicly accessible green and wild spaces within urban environments, and use their role as major nodes in transport infrastructure to change that infrastructure to support active travel alternatives.ivThe Land Ethic reminds us that a community (human or land) is not healthy if its flourishing cannot be sustainably maintained. An essential component of Anthropocene health justice buy kamagra online without prescription is intergenerational justice. Contemporary industrialised healthcare has an unsustainable ecological footprint. Continuing with such a model of care would serve only to mortgage the health of future generations for buy kamagra online without prescription the sake of those living now.
Ecologically conscious practice must take seriously the sorts of downstream, distributed consequences of activity that produce anthropogenic global health threats, and evaluate to what extent our most intensive healthcare practices truly serve to promote public and planetary health. It is not enough for the clinician to assume that our resource usage is a necessary evil in the pursuit of best clinical outcomes, for it is already apparent that much of our environmental exploitation is of minimal or even negative long-term value. The work of the National Health Service (NHS) Sustainable Development Unit has seen a 10% reduction buy kamagra online without prescription in greenhouse gas emissions in the NHS from 2007 to 2015 despite an 18% increase in clinical activity,20 while different models of care used in less industrialised nations manage to provide high-quality health outcomes in less resource-intensive fashion.21ConclusionOur present problem is one of attitudes and implements. We are remodelling the Alhambra with a steam-shovel. We shall hardly relinquish the steam-shovel, which after all has many good points, but we are in need of gentler buy kamagra online without prescription and more objective criteria for its successful use.
(Leopold, âThe Land Ethicâ1, p 226)The moral challenges of the Anthropocene do not solely confront health workers. But the potentially catastrophic health effects of anthropogenic global environmental change, and the contribution of healthcare activity to driving these changes provide a specific and unique imperative for action from health workers.Yet it is hard to articulate this imperative in the language of contemporary clinical ethics, ill equipped for this intrusion of Gaia. Justice in the Anthropocene requires us buy kamagra online without prescription to be able to adopt a perspective from which these changes no longer appear as unexpected intrusions, but that acknowledges the land community as part of our moral community. The Land Ethic articulates an understanding of justice that is holistic, structural, intergenerational, and rejects anthropocentrism. This understanding seeks not to supplant, but buy kamagra online without prescription to augment, our existing one.
It aims to do so by helping us to develop an âecological conscienceâ, seeing ourselves as âplain member and citizenâ of the land community. The Land Ethic does not provide a step-by-step guide to just action. Nor does it definitively buy kamagra online without prescription adjudicate on how to balance the interests of our patients, other populations now and in the future, and the planet. It could, however, help us on the first step towards that changeâshowing how to cultivate the âinternal change in our intellectual emphasis, loyalties, affections, and convictionsâ1 (pp 209â210) necessary to realise the virtues of just healthcare in the Anthropocene.AcknowledgmentsThis essay was written as a submission for the BMA Presidential Essay Prize. I am grateful to the organisers and judging panel for the opportunity..
Justice, one of the four Beauchamp and Childress prima facie basic principles buy kamagra gel of biomedical ethics, is explored in two how do i get kamagra excellent papers in the current issue of the journal. The papers stem from a British Medical Association (BMA) essay competition on justice and fairness in medical practice and policy. Although the competition was open to (almost) all comers, of the 235 entries both the winning paper by Alistair Wardrope1 and the highly commended runner-up by Zoe Fritz how do i get kamagra and CaitrÃona Cox2 were written by practising doctorsâa welcome indication of the growing importance being accorded to philosophical reflection about medical practice and practices within medicine itself.
Both papers are thoroughly thought provoking and represent two very different approaches to the topic. Each deserves a careful read.The competition was a component of a BMA 2019/2020 âPresidential projectâ on fairness and justice and asked candidates to âuse ethical reasoning and theory to tackle challenging, practical, contemporary, problems in health care and help provide a solution based on an explained and defended sense of fairness/justiceâ.In this guest editorial Iâd like to explain why, in 2018 on becoming president-elect of the BMA, I chose the theme of justice and fairness in medical ethics for my 2019â2020 Presidential projectâand why in a world of massive and ever-increasing and remediable health inequalities biomedical ethics requires greater international and interdisciplinary efforts to try to reach agreement on the need to achieve greater âhealth justiceâ and to reach agreement on what that commitment actually means and on what in practice it requires.First, some background. As president I was offered the wonderful opportunity to pursue, with the organisationâs formidable assistance, a âprojectâ consistent with how do i get kamagra the BMAâs interests and values.
As a hybrid of general medical practitioner and philosopher/medical ethicist, and as a firm defender of the Beauchamp and Childress four principles approach to medical ethics,3 I chose to try to raise the ethical profile of justice and fairness within medical ethics.My first objective was to ask the BMA to ask the World Medical Association (WMA) to add an explicit commitment âto strive to practise fairly and justly throughout my professional lifeâ to its contemporary version of the Hippocratic Oathâthe Declaration of Geneva4âand to the companion document the International Code of Medical Ethics.5 The stimulus for this proposal was the WMAâs addition in 2017 of the principle of respect for patientsâ autonomy. Important as how do i get kamagra that addition is, it is widely perceived (though in my own view mistakenly) as being too much focused on individual patients and not enough on communities, groups and populations. The simple addition of a commitment to fairness and justice would provide a âbalancingâ moral commitment.Adding the fourth principleIt would also explicitly add the fourth of those four prima facie moral commitments, increasingly widely accepted by doctors internationally.
Two of themâbenefiting our patients (beneficence) and doing so with as little harm as possible (non-maleficence)âhave been an integral part of medical ethics since Hippocratic times. Respect for autonomy and justice are very much more recent additions to how do i get kamagra medical ethics. The WMA, having added respect for autonomy to the Declaration of Geneva, should, I proposed, complete the quartet by adding the âbalancingâ principle of fairness and justice.Since the Declaration is unlikely to be revised for several years, it seems likely that the proposal to add to it an explicit commitment to practise fairly and justly will have to wait.
However, an explicit commitment to justice and fairness has, at the BMAâs request, been added to the draft of the International Code of Medical Ethics and it seems reasonable to hope and expect that it will remain in the final document.Adding a commitment to fairness and justice is the easy part! how do i get kamagra. Few doctors would on reflection deny that they ought to try to practise fairly and justly. It is far more difficult to say what is actually meant by this.
Two additional components of my Presidential projectâthe essay competition and a how do i get kamagra conference (which with luck will have been held, virtually, shortly before publication of this editorial)âsought to help elucidate just what is meant by practising fairly and justly.One of the most striking features of the essay competition was the readiness of many writers to point to injustices in the context of medical practice and policy and describe ways of remedying them, but without giving a specific account of justice and fairness on the basis of which the diagnosis of injustice was made and the remedy offered.Wardropeâs winning essay comes close to such an approach by challenging the implied premise that an account of justice and fairness must provide some such formal theory. In preference, he points to the evident injustice and unsustainability of humansâ degradation of âthe Landâ and its atmosphere and its inhabitants and then challenges some assumptions of contemporary philosophy and ethics, especially what he sees as their anthropocentric and individualistic focus. Instead, he invokes Leopold Aldoâs how do i get kamagra âLand Ethicâ (as well as drawing in aid Isabelle Stengerâs focus on âthe intrusion of Gaiaâ).
In his thoughtful and challenging paper, he seeks to refocus our ethicsâincluding our medical ethics and our sense of justice and fairnessâon mankindâs exploitative threat, during this contemporary âanthropoceneâ stage of evolution, to the continuing existence of humans and of all forms of life in our âbiotic communityâ. As remedy, the author, allying his approach to those of contemporary virtue ethics, recommends the beneficial outcomes that would be brought about by a sense of fairness and justiceâa developed and sensitive âecological conscienceâ as he calls itâthat embraces the interests of the entire biotic community of which we humans are but a part.Fritz and Cox pursue a very different and philosophically more conventional approach to the essay competitionâs question and offer a combination and development of two established philosophical theories, those of John Rawls and Thomas Scanlon, to provide a philosophically robust and practically beneficial methodology for justice and fairness in medical practice and policy. Briefly summarised, they recommend a two-stage approach how do i get kamagra for healthcare justice.
First, those faced with a problem of fairness or justice in healthcare or policy should use Thomas Scanlonâs proposed contractualist approach whereby reasonable people seek solutions that they and others could not âreasonably rejectâ. This stage would involve committees of decision-makers and representatives of relevant stakeholders looking at the immediate and longer term impact on existing stakeholders of proposed solutions. They would then check those solutions against how do i get kamagra substantive criteria of justice derived from Rawlsâ theory (which, via his theoretical device of the âveil of ignoranceâ, Rawls and the authors argue that all reasonable people can be expected to accept!.
). The Rawlsian criteria relied on by Fritz and Cox how do i get kamagra are equity of access to healthcare. The âdifference principleâ whereby avoidable inequalities of primary goods can only be justified if they benefit the most disadvantaged.
The just savings principle, of particular importance for ensuring intergenerational justice and sustainability. And a criterion of increased openness, transparency and accountability.It would of course be naïve to how do i get kamagra expect a single universalisable solution to the question âwhat do we mean by fairness and justice in health care?.  As the papers by Wardrope1 and Fritz and Cox2 demonstrate, there can be very wide differences of approach in well-defended accounts.
My own hope for how do i get kamagra my project is to emphasise the importance first of committing ourselves within medicine to practising fairly and justly in whatever branch we practise. And then to think carefully about what we do mean by that and act accordingly.Following AristotleFor my own part, over 40 years of looking, I have not yet found a single substantive theory of justice that is plausibly universalisable and have had to content myself with Aristotleâs formal, almost content-free but probably universalisable theory, according to which equals should be treated equally and unequals unequally in proportion to the relevant inequalitiesâwhat some health economists refer to as horizontal and vertical justice or equity.6Beauchamp and Childress in their recent eighth and âperhaps finalâ edition of their foundational âPrinciples of biomedical ethicsâ1 acknowledge that â[t]he construction of a unified theory of justice that captures our diverse conceptions and principles of justice in biomedical ethics continues to be controversial and difficult to pin downâ.They still cite Aristotleâs formal principle (though with less explanation than in their first edition back in 1979) and they still believe that this formal principle requires substantive or âmaterialâ content if it is to be useful in practice. They then describe six different theories of justiceâfour âtraditionalâ (utilitarian, libertarian, communitarian and egalitarian) and two newer theories, which they suggest may be more helpful in the context of health justice, one based on capabilities and the other on actual well-being.They again end their discussion of justice with their reminder that âPolicies of just access to health care, strategies of efficiencies in health care institutions, and global needs for the reduction of health-impairing conditions dwarf in social importance every other issue considered in this bookâ â¦â¦.
Âevery society must ration its resources but many societies can close gaps in fair rationing more conscientiously than they how do i get kamagra have to dateâ [emphasis added]. And they go on to stress their own support for ârecognition of global rights to health and enforceable rights to health care in nation-statesâ.For my own part I recommend, perhaps less ambitiously, that across the globe we extract from Aristotleâs formal theory of justice a starting point that ethically requires us to focus on equality and always to treat others as equals and treat them equally unless there are moral justifications for not doing so. Where such justifications exist we should say what they are, explain the moral assumptions that justify them and, to the extent possible, seek how do i get kamagra the agreement of those affected.IntroductionIt did not occur to the Governor that there might be more than one definition of what is good ⦠It did not occur to him that while the courts were writing one definition of goodness in the law books, fires were writing quite another one on the face of the land.
(Leopold, âGood Oakâ1, pp 10â11)As I wrote the abstract that would become this essay, wildfires were spreading across Australiaâs east coast. By the time I was invited to write the essay, back-to-back winter storms were flooding communities all around my home. The essay has been written in moments of respite between shifts during the erectile dysfunction treatment kamagra how do i get kamagra.
Every one of these events was described as âunprecedentedâ. Yet each is becoming increasingly likely, and that due to our interactions with our environment.Public discourse surrounding these events is dominated by questions of justice and fairness. How to balance competing imperatives of protecting individual lives against risk of spreading contagion how do i get kamagra.
How best to allocate scarce resources like intensive care beds or mechanical ventilators. The conceptual tools of clinical ethics are how do i get kamagra well tailored to these sorts of questions. The rights of the individual versus the community, issues of distributive justiceâthese are familiar to anyone with even a passing acquaintance with its canonical debates.What biomedical ethics has remained largely silent on is how we have been left to confront these decisions.
How human activity has eroded Earthâs life support systems to make the âunprecedentedâ the new normal. A medical ethic fit for the Anthropoceneâour (still tentative) geological epoch defined by human influence on natural systemsâmust be able not just to react to the consequences of our exploitation of the natural world, but reimagine our relationship with it.Those reimaginations already exist, if how do i get kamagra we know where to look for them. The âLand Ethicâ of the US conservationist Aldo Leopold offers one such vision.i Developed over decades of experience working in and teaching land management, the Land Ethic is most famously formulated in an essay of the same name published shortly before Leopoldâs death fighting a wildfire on a neighbourâs farm.
It begins with a reinterpretation of the ethical relationship between humanity and the âland communityâ, the ecosystems we live within and depend how do i get kamagra upon. Moving us from âconquerorâ to âplain member and citizenâ of that community1 (p 204). Land ceases to be a resource to be exploited for human need once we view ourselves as part of, and only existing within, the land community.
Our moral evaluations shift how do i get kamagra consonantly:A thing is right when it tends to preserve the integrity, stability, and beauty of the biotic community. It is wrong when it tends otherwise.1 (pp 224â225)The justice of the Land Ethic questions many presuppositions of biomedical ethics. By valuing the community in itselfâin a way irreducible to the welfare of its membersâit steps away from how do i get kamagra the individualism axiomatic in contemporary bioethics.2 Viewing ourselves as citizens of the land community also extends the moral horizons of healthcare from a solely human focus, taking seriously the interests of the non-human members of that community.
Taking into account the âstabilityâ of the community requires intergenerational justiceâthat we consider those affected by our actions now, and their implications for future generations.3 The resulting vision of justice in healthcareâone that takes climate and environmental justice seriouslyâcould offer health workers an ethic fit for the future, demonstrating ways in which practice must change to do justice to patients, public and planetânow and in years to come.Healthcare in the AnthropoceneSeemeth it a small thing unto you to have fed upon good pasture, but ye must tread down with your feet the residue of your pasture?. And to have drunk of the clear waters, but ye must foul the residue with your feet?. (Ezekiel 34:18, quoted in Leopold, âConservation in the Southwestâ4, p 94)The majority of the development of human societies worldwideâincluding all of recorded human how do i get kamagra historyâhas taken place within a single geological epoch, a roughly 11â600 yearlong period of relative warmth and climatic stability known as the Holocene.
That stability, however, can no longer be taken for granted. The epoch that has sustained most of human development is giving way to one shaped by the planetary consequences of that developmentâthe Anthropocene.The Anthropocene is marked by accelerating degradation of the ecosystems that have sustained human societies. Human activity is already estimated to have raised global temperatures 1°C above preindustrial levels, and if emissions continue at current levels we are likely how do i get kamagra to reach 1.5°C between 2030 and 2052.5 The global rate of species extinction is orders of magnitude higher than the average over the past 10 million years.6 Ocean acidification, deforestation and disruption of nitrogen and phosphorus flows are likely at or beyond sustainable planetary boundaries.7Yet this period has also seen rapid (if uneven) improvements in human health, with improved life expectancy, falling child mortality and falling numbers of people living in extreme poverty.
The 2015 report of the Rockefeller Foundation-Lancet Commission on planetary health explained this dissonance in stark terms. Âwe have been mortgaging the health of future generations to realise economic and development gains in the present.â7In how do i get kamagra the instrumental rationality of modernity, nature has featured only as inexhaustible resource and infinite sink to fuel social and economic ends. But this disenchanted worldview can no longer hide from the implausibility of these assumptions.
It cannot resist what the philosopher Isabelle Stengers has called âthe intrusion of Gaiaâ.8 The present kamagraâmade more likely by deforestation, land use change and biodiversity loss9âis just the most immediately salient of these intrusions. Anthropogenic environmental changes are increasing undernutrition, increasing range and transmissibility how do i get kamagra of many vectorborne and waterborne diseases like dengue fever and cholera, increasing frequency and severity of extreme weather events like heatwaves and wildfires, and driving population exposure to air pollutionâwhich already accounts for over 7 million deaths annually.10These intrusions will shape healthcare in the Anthropocene. This is because health workers will have to deal with their consequences, and because modern industrialised healthcare as practised in most high-income countriesâand considered aspirational elsewhereâwas borne of the same worldview that has mortgaged the health of future generations.
The health sector in the USA is estimated to account for 8% of the countryâs greenhouse gas footprint.11 Pharmaceutical production and waste causes how do i get kamagra more local environmental degradation, accumulating in water supplies with damaging effects for local flora and fauna.12 Public health has similarly embraced short-term gains with neglect of long-term consequences. Health messaging was instrumental to the development and popularisation of many disposable and single-use products, while a 1947 report funded by the Rockefeller Foundation (who would later fund the landmark 2015 Lancet report on planetary health) popularised the high-meat, high-dairy âAmericanâ dietâdependent on fossil fuel-driven intensive agricultural practicesâas the healthy ideal.13Healthcare fit for the Anthropocene requires a shift in perspectives that allows us to see and work with the intrusion of Gaia. But can dominant approaches in bioethics incorporate that shift?.
A perfect how do i get kamagra moral stormWe have built a beautiful piece of social machinery ⦠which is coughing along on two cylinders because we have been too timid, and too anxious for quick success, to tell the farmer the true magnitude of his obligations. (Leopold, âThe Ecological Conscienceâ4, p 341)At local, national and international scales, the lifestyles of the wealthiest pose an existential threat to the poorest and most marginalised in society. Our actions now are depriving future generations of how do i get kamagra the environmental prerequisites of good health and social flourishing.
If justice means, as Ranaan Gillon parses it, âthe moral obligation to act on the basis of fair adjudication between competing claimsâ,14 then this state of affairs certainly seems unjust. However, the tools available for grappling with questions of justice in bioethics seem ill equipped to deal with these sorts of injustice.To illustrate this problem, consider how Gillon further fleshes out his description of justice. In terms how do i get kamagra of fair distribution of scarce resources, respect for peopleâs rights, and respect for morally acceptable laws.
The first of theseâlabelled distributive justiceâconcerns how fairly to allot finite resources among potential beneficiaries. Classic problems of distributive justice in healthcare concern a group of people at a particular time (usually patients), who could each benefit from a particular resource (historically, discussions have often focused on transplant organs. More recently, intensive care beds and how do i get kamagra ventilators have come to the fore).
But there are fewer of these resources than there are people with a need for them. Such discussions are not easy, but they are at least how do i get kamagra familiarâwe know where to begin with them. We can consider each partyâs need, their potential to benefit from the resource, any special rights or other claims they may have to it, and so forth.
The distribution of benefits and harms in the Anthropocene, however, does not comfortably fit this formalism. It is one thing to say that there is but one intensive care bed, from which Smith has a good chance of gaining another year of life, Jones a poor chance, and so offer it how do i get kamagra to Smith. Another entirely to say that production of the materials consumed in Smithâs care has contributed to the degradation of scarce water supplies on the other side of the globe, or that the unsustainable pattern of energy use will affect innumerable other future persons in poorly quantifiable ways through fuelling climate change.
The calculations of distributive justice are how do i get kamagra well suited to problems where there are a set pool of potential beneficiaries, and the use of the scarce resources available affects only those within that pool. But global environmental problems do not fit this patternâthe effects of our actions are spatially and temporally dispersed, so that large numbers of present and future people are affected in different ways.Nor can this problem be readily addressed by turning to Gillonâs second category of obligations of justice, those grounded in human rights. For while it might be plausible (if not entirely uncontroversial) to say that those communities whose water supplies are degraded by pharmaceutical production have a right to clean water, it is another thing entirely to say that Smithâs healthcare is directly violating that right.
It would not be true to say that, were it not for the how do i get kamagra resources used in caring for Smith, that the communities in question would face no threat to water securityâindeed, they would likely make no appreciable difference. Similarly for the effects of Smithâs care on future generations facing accelerating environmental change.iiThe issue here is of fragmentation of agency. While it is not the case that Smithâs care is directly responsible for these environmental harms, the how do i get kamagra cumulative consequences of many such actsâand the ways in which these acts are embedded in particular systems of energy generation, waste management, international trade, and so onâare reliably producing these harms.
The injustice is structural, in Iris Marion Youngâs terminologyâarising from the ways in which social structures constrain individuals from pursuing certain courses of action, and enable them to follow others, with side effects that cumulatively produce devastating impacts.15Gillon describes the third component of justice as respect for morally acceptable laws. But there is little reason to believe that existing legal frameworks provide sufficient guidance to address these structural injustices. While the intricacies of global governance are well beyond what I can hope to address here, the stark fact remains that, despite the international commitment of the 2015 Paris Agreement to attempt to keep global temperature rise to 1.5°C above preindustrial levels, the Intergovernmental Panel on Climate Change estimates that present national commitmentsâeven if these are substantially increased in coming yearsâwill take us well beyond that target.5 Confronted by such institutional inadequacy, respect for the rule of law is inadequate to remedy injustice.The confluence of these particular featuresâdispersion of causes and effects, fragmentation of agency and institutional inadequacyâmakes it difficult for how do i get kamagra us to reason ethically about the choices we have to make.
Stephen Gardiner calls this a âperfect moral stormâ.16 Each of these factors individually would be difficult to address using the resources of contemporary biomedical ethics. Their convergence makes it seem insurmountable.This perfect storm was not, however, unpredictable. Van Rensselaer Potter, a professor of Oncology responsible for introducing the term âbioethicsâ into Anglophone discourse, observed that since he coined the phrase, the study of bioethics had diverged from his original usage (governing all issues at the how do i get kamagra intersection of ethics and the biological sciences) to a narrow focus on the moral dilemmas arising in interactions between individuals in biomedical contexts.
Potter predicted that the short-term, individualistic and medicalised focus of this approach would result in a neglect of population-level and ecological-level issues affecting human and planetary health, with catastrophic consequences.17 His proposed solution was a new âglobal bioethicsâ, grounded in a new understanding of humanityâs position within planetary systemsâone articulated by the Land Ethic.The Land EthicA land ethic changes the role of Homo sapiens from conqueror of the land-community to plain member and citizen of it. It implies respect for his fellow-members, and also respect for the community as such.iii (Leopold, âThe Land how do i get kamagra Ethicâ1, p 204)Developed throughout a career in forestry, conservation and wildlife management, the Land Ethic is less an attempt to provide a set of maxims for moral action, than to shift our perspectives of the moral landscape. In his working life, Aldo Leopold witnessed how actions intended to optimise short-term economic outcomes eroded the environments on which we dependâwhether soil degradation arising from intensive farming and deforestation, or disruption of freshwater ecosystems by industrial dairy farming.
He also saw that contemporary morality remained silent on such actions, even when their consequences were to the collective detriment of all.Leopold argued that a series of âhistorical accidentsâ left our morality particularly ill suited to handle these intrusions of Gaiaâwith a worldview that considered them âintrusionsâ, rather than the predictable response of our biotic community. These âaccidentsâ were how do i get kamagra. The unusual resilience of European ecological communities to anthropogenic interference (England survived an almost wholesale deforestation without consequent loss of ecosystem resilience, while similar changes elsewhere resulted in permanent environmental degradation).
And the legacy of European settler colonialism, meaning that an ethic arising in these particular conditions came how do i get kamagra to dominate global social arrangements4 (p 311). The first of these supported a worldview in which âLand ⦠is ⦠something to be tamed rather than something to be understood, loved, and lived with. Resources are still regarded as separate entities, indeed, as commodities, rather than as our cohabitants in the land communityâ4 (p 311).
The second how do i get kamagra enabled the marginalisation of other views. In this genealogy, Leopold anticipated the perfect moral storm discussed above. His intent with the Land Ethic was to navigate it.There are three key components how do i get kamagra of the Land Ethic that comprise the first three sections of Leopoldâs final essay on the subject.
(1) the âcommunity conceptâ that allows communities as wholes to have intrinsic value. (2) the âethical sequenceâ that situates the value of such communities as extending, not replacing, values assigned to individuals. And (3) the âecological conscienceâ that views ethical action not in terms of following a particular code, but in developing appropriate moral perception.The community conceptThe most widely quoted passage of Leopoldâs opusâalready cited above, and frequently (mis)taken as a summary maxim of the ethicâstates that:A thing is right when how do i get kamagra it tends to preserve the integrity, stability, and beauty of the biotic community.
It is wrong when it tends otherwise.1 (pp 224â225)This passage makes the primary object of our moral responsibilities âthe biotic communityâ, a term Leopold uses interchangeably with the âland communityâ. Leopoldâs community concept is notable in at least three respects. Its holismâan embrace of the moral significance of communities in a way how do i get kamagra that is not simply reducible to the significance of its individual members.
Its understanding of communities as temporally extended, placing importance on their âintegrityâ and âstabilityâ. And its rejection of anthropocentrism, affording humanity a place as âplain member and citizenâ how do i get kamagra of a broader land community.Individualism is so prevalent in biomedical ethics that it is scarcely argued for, instead forming part of the âbackground constellation of valuesâ2 tacitly assumed within the field. We are used to evaluating the well-being of a community as a function of the well-being of its individual membersâthis is the rationale underlying quality-adjusted life year calculations endemic within health economics, and most discussions of distributive justice adopt some variation of this approach.
Holism instead proposes that this makes no more sense than evaluating a personâs well-being as an aggregate of the well-being of their individual organs. While we can sensibly talk about peopleâs hearts, livers or kidneys, their health is defined in terms of and constitutively dependent on how do i get kamagra the health of the person as a whole. Similarly, holism proposes, while individuals can be identified separately, it only makes sense to talk about them and their well-being in the context of the larger biotic community which supports and defines us.Holism helps us to negotiate the issues that confront individualistic accounts of collective well-being in Anthropocene health injustices.
In the previous section, we found in the environmental consequences of industrialised healthcare that it is difficult to identify which parties in particular are harmed, how do i get kamagra and how much each individual action contributes to those harms. But our intuition that the overall result is unfair or unjust is itself a holistic assessment of the overall outcome, not dependent on our calculation of the welfare of every party involved. Holism respects the intuition that saysâno matter the individuals involvedâa world where people now exploit ecological resources in a fashion that deprives people in the future of the prerequisites of survival, is worse than one where communities now and in the future live in a sustainable relationship with their environment.The second aspect of Leopoldâs community concept is that the community is something that does not exist at a single time and placeâit is defined in terms of its development through time.
Promoting the âintegrityâ and âstabilityâ of the community requires that we not just consider its immediate interests, but how do i get kamagra how that will affect its long-term sustainability or resilience. We saw earlier the difficulties in trying to say just who is harmed and how when we approach harm to future generations individualistically. But from the perspective of the Land Ethic, when we exploit environmental resources in ways that will have predictable damaging results for future generations, the object of our harm is not just some how do i get kamagra purely notional future person.
It is a presently existing, temporally extended entityâthe community of which they will be part.Lastly, Leopoldâs community is quite consciously a bioticânot merely humanâcommunity. Leopold defines the land community as the open network of energy and mineral exchange that sustains all aspects of that network:Land⦠is not merely soil. It is how do i get kamagra a fountain of energy flowing through a circuit of soils, plants, and animals.
Food chains are the living channels which conduct energy upward. Death and decay return it to the soil. The circuit how do i get kamagra is not closed.
Some energy is dissipated in decay, some is added by absorption, some is stored in soils, peats, and forests, but it is a sustained circuit, like a slowly augmented revolving fund of life.4 (pp 268â269)While the components within this network may change, the land community as a whole remains stable when the overall complexity of the network is not disruptedâother components are able to adjust to these changes, or new ones arise to take their place.ivThe normative inference Leopold makes from his understanding of the land community is this. It makes no sense to how do i get kamagra single out individual entities within the community as being especially valuable or useful, without taking into account the whole community upon which they mutually depend. To do so is self-defeating.
By privileging the interests of a few members of the community, we ultimately undermine the prerequisites of their existence.The ethical sequenceThe Land Ethicâs holism is in fact its most frequently critiqued feature. Its emphasis on the value of the biotic community leads some to allege how do i get kamagra a subjugation of individual interests to the needs of the environment. This critique neglects how Leopold positions the Land Ethic in what he calls the âethical sequenceâ.
This is the gradual extension of scope of ethical considerations, both in terms of the complexity of social interactions they cover (from interactions between two people, to the structure of progressively larger social groups), and in the kinds of person how do i get kamagra they acknowledge as worthy of moral consideration (as we resist, for example, classist, sexist or racist exclusions from personhood).This sequence serves less as a description of the history of morality, than a prescription for how we should understand the Land Ethic as adding to, rather than supplanting, our responsibilities to others. We do not argue that taking seriously health workersâ responsibilities for public health and health promotion supplants their duties to the patients they work with on a daily basis. Similarly, the Land Ethic implies ârespect for [our] fellow members, and also respect for the community as suchâ1 (p 204).
At times, our responsibilities towards these different parties how do i get kamagra may come into tension. But balancing these responsibilities has always been part of the work of clinical ethics.The ecological conscienceIf the community concept gives a definition of the good, and the ethical sequence situates this definition within the existing moral landscape, neither offers an explicit decision procedure to guide right action. In arguing for the âecological conscienceâ, Leopold explains his rationale for not attempting how do i get kamagra to articulate such a procedure.
In his career as conservationist, Leopold witnessed time and again laws nominally introduced in the name of environmental protection that did little to achieve their long-term goals, while exacerbating other environmental threats.v This is not surprising, given the âperfect moral stormâ of Anthropocene global health and environmental threats discussed above. The cumulative results of apparently innocent actions can be widespread and damaging.Leopoldâs response to this problem is to advocate the cultivation of an âecological conscienceâ. What is needed to promote a healthy human relationship with the land community is not for us to be told exactly how and how not to act in the face of environmental health threats, but rather to shift our view of the land from âa commodity belonging to usâ towards âa how do i get kamagra community to which we belongâ1 (p viii).
To understand what the Land Ethic requires of us, therefore, we should learn more about the land community and our relationship with it, to develop our moral perception and extend its scope to embrace the non-human members of our community.Seen in this light, the Land Ethic shares much in common with virtue ethics, where right action is defined in terms of what the moral agent would do, rather than vice versa. But rather than the Eudaimonia of individual human flourishing proposed by Aristotle, the phronimos of the Land Ethic sees their telos coming from their position within the land community. While clinical virtue ethicists have traditionally taken the virtues of medical practice to be grounded in the interaction with individual patients, the realities of healthcare in the Anthropocene mean that limiting our moral perceptions in this way would ultimately be self-defeatingâhurting those very patients we mean to serve (and many how do i get kamagra more besides).18 The virtuous clinician must adopt a view of the moral world that can focus on a person both as an individual, and simultaneously as member of the land community.
I will close by exploring how adopting that perspective might change our practice.Justice in the AnthropoceneFailing this, it seems to me we fail in the ultimate test of our vaunted superiorityâthe self-control of environment. We fall back how do i get kamagra into the biological category of the potato bug which exterminated the potato, and thereby exterminated itself. (Leopold, âThe River of the Mother of Godâ4, p 127)I have articulated some of the challenges healthcare faces in the Anthropocene.
I have suggested that the tools presently available to clinical ethics may be inadequate to meet them. The Land Ethic invites us to reimagine our position in and relationship with the land community how do i get kamagra. I want to close by suggesting how the development of an ecological conscience might support a transition to more just healthcare.
I will how do i get kamagra not endeavour to give detailed prescriptions for action, given Leopoldâs warnings about the limitations of such codifications. Rather, I will attempt to show how the cultivation of an ecological conscience might change our perception of what justice demands. Following the tradition of virtue ethics with which the Land Ethic holds much in common, this is best achieved by looking at models of virtuous action, and exploring what makes it virtuous.19Industrialised healthcare developed within a paradigm that saw the environment as inert resource and held that the scope of clinical ethics ranged only over the clinicianâs interaction with their patients.
When we begin to see clinician and patient not as standing apart from the environment, but as âmember and citizen of the land communityâ, their how do i get kamagra relationship with one another and with the world around them changes consonantly. The present kamagra has only begun to make commonplace the idea that health workers do not simply treat infectious diseases, but interact with them in a range of ways, including as vectorâand as a result our moral obligations in confronting them may extend beyond the immediate clinical encounter, to cover all the other ways we may contract or spread disease. But we may be responsible for disease outbreaks with conditions other than erectile dysfunction treatment, and in ways beyond simply how do i get kamagra becoming infected.
The development of an ecological conscience would show how our practices of consumption may fuel deforestation that accelerates the emergence of novel pathogens, or support intensive animal rearing that drives antibiotic resistance.18The Land Ethic also challenges us not to abstract our work away from the places in which it takes place. General practitioner surgeries and hospitals are situated within social and land communities alike, shaping and shaped by them. These spaces can how do i get kamagra be used in ways that support or undermine those communities.
Surgeries can work to empower their communities to pursue more sustainable and healthy diets by doubling as food cooperatives, or providing resources and âsocial prescriptionsâ for increased walking and cycling. Hospitals can use their extensive real estate to provide publicly accessible green and wild spaces within urban environments, and use their role as major nodes in transport infrastructure to change that infrastructure to support active travel alternatives.ivThe Land Ethic reminds us that a community (human or land) is not healthy if its flourishing cannot be sustainably maintained. An essential component of Anthropocene health justice is intergenerational justice how do i get kamagra.
Contemporary industrialised healthcare has an unsustainable ecological footprint. Continuing with such a model of how do i get kamagra care would serve only to mortgage the health of future generations for the sake of those living now. Ecologically conscious practice must take seriously the sorts of downstream, distributed consequences of activity that produce anthropogenic global health threats, and evaluate to what extent our most intensive healthcare practices truly serve to promote public and planetary health.
It is not enough for the clinician to assume that our resource usage is a necessary evil in the pursuit of best clinical outcomes, for it is already apparent that much of our environmental exploitation is of minimal or even negative long-term value. The work of the National Health Service (NHS) how do i get kamagra Sustainable Development Unit has seen a 10% reduction in greenhouse gas emissions in the NHS from 2007 to 2015 despite an 18% increase in clinical activity,20 while different models of care used in less industrialised nations manage to provide high-quality health outcomes in less resource-intensive fashion.21ConclusionOur present problem is one of attitudes and implements. We are remodelling the Alhambra with a steam-shovel.
We shall hardly relinquish the steam-shovel, which after all has many good points, but we are in how do i get kamagra need of gentler and more objective criteria for its successful use. (Leopold, âThe Land Ethicâ1, p 226)The moral challenges of the Anthropocene do not solely confront health workers. But the potentially catastrophic health effects of anthropogenic global environmental change, and the contribution of healthcare activity to driving these changes provide a specific and unique imperative for action from health workers.Yet it is hard to articulate this imperative in the language of contemporary clinical ethics, ill equipped for this intrusion of Gaia.
Justice in the Anthropocene requires us to be able to adopt a perspective from which these changes no how do i get kamagra longer appear as unexpected intrusions, but that acknowledges the land community as part of our moral community. The Land Ethic articulates an understanding of justice that is holistic, structural, intergenerational, and rejects anthropocentrism. This understanding how do i get kamagra seeks not to supplant, but to augment, our existing one.
It aims to do so by helping us to develop an âecological conscienceâ, seeing ourselves as âplain member and citizenâ of the land community. The Land Ethic does not provide a step-by-step guide to just action. Nor does it definitively adjudicate on how how do i get kamagra to balance the interests of our patients, other populations now and in the future, and the planet.
It could, however, help us on the first step towards that changeâshowing how to cultivate the âinternal change in our intellectual emphasis, loyalties, affections, and convictionsâ1 (pp 209â210) necessary to realise the virtues of just healthcare in the Anthropocene.AcknowledgmentsThis essay was written as a submission for the BMA Presidential Essay Prize. I am grateful to the organisers and judging panel for the opportunity..
October 20, kamagra gold vs viagra 2020 (TORONTO) â Canada Health Infoway (Infoway) and Aware MD are pleased to announce that http://sallyheston.com/portfolio-item/all-tied-up/ they have reached an agreement that will give more Canadians access to e-prescribing. PrescribeIT® is Infowayâs national e-prescribing service that enables kamagra gold vs viagra prescribers and pharmacists to electronically create, receive, renew and cancel prescriptions, while improving overall patient care through secure clinician messaging.Under the agreement, Aware MD will integrate its Cerebrum⢠electronic medical record (EMR) with PrescribeITâs solution infrastructure, with targeted completion by the second half of 2021. The specialists who use the Cerebrum⢠solution will be able to send prescriptions electronically from their EMR to the patientâs pharmacy of choice, and pharmacies will be able to request prescription renewals electronically from the patientâs specialist.
Aware MD provides kamagra gold vs viagra services to 400 cardiologists and radiologists in 104 clinics across Ontario, who in turn provide care to more than two million patients.âThis partnership with Infoway is very important for us because it will benefit the medical specialists who use our EMR solution and, more importantly, it will benefit the patients they care for,â said Anatoly Langer, MD, MSc, FRCPC, FACC, President of Aware MD. ÂThe days of hand written and faxed prescriptions are in the past, and PrescribeIT® is a step forward for all parties involved â physicians, pharmacists and patients.ââWe are excited to work with Aware MD to make PrescribeIT® available to the specialists across Ontario who use the Cerebrum⢠EMR solution,â said Jamie Bruce, Executive Vice President, Infoway. ÂBy eliminating the use of paper and faxed prescriptions, PrescribeIT® makes prescribing safer, more secure, kamagra gold vs viagra easier and more convenient, resulting in better health outcomes for Canadians.âAbout Aware MDAware MD Inc.
Is a Canadian company located in Toronto that has been in business since 2003. Cerebrum⢠is a proprietary workflow solution developed kamagra gold vs viagra by Aware MD Inc. For specialists kamagra gold vs viagra to manage busy multi-diagnostic practices.
It is a secure, intuitive and modular software program that can be customized to clinical needs. It represents the most comprehensive workflow solution kamagra gold vs viagra available today for specialists. Visit www.awaremd.com.About Canada Health InfowayInfoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada.
Through our investments, we help deliver better quality and access to care and more efficient delivery of health services for patients and kamagra gold vs viagra clinicians. Infoway is an independent, not-for-profit organization funded by the federal government. Visit www.infoway-inforoute.ca.About PrescribeIT®Canada Health Infoway is working with Health Canada, the provinces and territories, and industry stakeholders to develop, operate and maintain the kamagra gold vs viagra national e-prescribing service known as PrescribeIT®.
PrescribeIT® will serve all Canadians, pharmacies and prescribers and provide safer and more effective medication management by enabling prescribers to transmit a prescription electronically kamagra gold vs viagra between a prescriberâs electronic medical record (EMR) and the pharmacy management system (PMS) of a patientâs pharmacy of choice. PrescribeIT® will protect Canadiansâ personal health information from being sold or used for commercial activities. Visit www.PrescribeIT.ca.-30-Media Inquiries Karen SchmidtDirector, Corporate/Internal CommunicationsCanada Health Infoway(416) 886-4967 Email UsFollow @InfowayInquiries about PrescribeIT®September 24, her comment is here 2020 (TORONTO) â kamagra gold vs viagra Canada Health Infoway (Infoway) and CloudMD are pleased to announce that they have reached an agreement to advance e-prescribing in Canada.
PrescribeIT® is Infowayâs national e-prescribing service that enables prescribers and pharmacists to electronically create, receive, renew and cancel prescriptions, while improving overall patient care through secure clinician messaging.Under the agreement, CloudMD will integrate its Juno electronic medical record (EMR) with PrescribeITâs solution infrastructure. CloudMD is kamagra gold vs viagra aiming to have the technical work completed in early 2021. Once complete, physicians and nurse practitioners who offer virtual consultations with patients will be able to send prescriptions electronically from their EMR to the patientâs pharmacy of choice, and pharmacies will be able to request prescription renewals electronically from the patientâs prescriber.âWe are excited to partner with Infoway because we believe a national, modern e-prescribing service will engender greater patient trust and confidence in prescriptions,â said Essam Hamza, MD, Chief Executive Officer of CloudMD.
ÂThe enhanced security offered by PrescribeIT® will be beneficial to health providers and patients who use CloudMDâs services.âCloudMD provides virtual medical care to a combined network of 376 clinics, more than 3,000 licensed kamagra gold vs viagra practitioners and almost three million patients through its technology components.âWe look forward to working with CloudMD to make PrescribeIT® more widely available across the country,â said Jamie Bruce, Executive Vice President, Infoway. ÂPrescribeIT® makes kamagra gold vs viagra prescribing safer, more secure, easier and more convenient by eliminating the use of paper and faxed prescriptions, resulting in better health outcomes for Canadians.âAbout CloudMDCloudMD (TSXV. DOC, OTC.
DOCRF) is digitizing the delivery of healthcare by providing patients access to all kamagra gold vs viagra points of their care from their phone, tablet or desktop computer. The Company offers SAAS based health technology solutions to medical clinics across Canada and has developed proprietary technology that delivers quality healthcare through the combination of connected primary care clinics, telemedicine and artificial intelligence (AI). CloudMD currently provides service to a combined ecosystem kamagra gold vs viagra of 376 clinics, more than 3,000 licensed practitioners and almost three million patient charts across its servers.
Visit cloudmd.ca.About Canada Health InfowayInfoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we help deliver better quality and access to care and more efficient delivery of health services for patients kamagra gold vs viagra and clinicians. Infoway is an independent, not-for-profit organization funded by the kamagra gold vs viagra federal government.
Visit www.infoway-inforoute.ca.About PrescribeIT®Canada Health Infoway is working with Health Canada, the provinces and territories, and industry stakeholders to develop, operate and maintain the national e-prescribing service known as PrescribeIT®. PrescribeIT® will serve all Canadians, pharmacies and prescribers and provide safer and more effective medication management by enabling prescribers to transmit a prescription electronically between a prescriberâs electronic medical record (EMR) and the pharmacy management kamagra gold vs viagra system (PMS) of a patientâs pharmacy of choice. PrescribeIT® will protect Canadiansâ personal health information from being sold or used for commercial activities.
Visit www.PrescribeIT.ca.-30-Media Inquiries Karen SchmidtDirector, kamagra gold vs viagra Corporate/Internal CommunicationsCanada Health Infoway(416) 886-4967 Email UsFollow @InfowayJulia BeckerVice President, Investor RelationsCloudMDThis email address is being protected from spambots. You need JavaScript enabled to view it.Inquiries about PrescribeIT®.
October 20, 2020 (TORONTO) how do i get kamagra â Canada Health Infoway (Infoway) and Aware MD are pleased to announce that they have reached an agreement that will buy kamagra oral jelly online australia give more Canadians access to e-prescribing. PrescribeIT® is Infowayâs national e-prescribing service that enables prescribers and how do i get kamagra pharmacists to electronically create, receive, renew and cancel prescriptions, while improving overall patient care through secure clinician messaging.Under the agreement, Aware MD will integrate its Cerebrum⢠electronic medical record (EMR) with PrescribeITâs solution infrastructure, with targeted completion by the second half of 2021. The specialists who use the Cerebrum⢠solution will be able to send prescriptions electronically from their EMR to the patientâs pharmacy of choice, and pharmacies will be able to request prescription renewals electronically from the patientâs specialist. Aware MD provides services to 400 cardiologists and radiologists in 104 clinics across Ontario, who in turn provide care to more than two million patients.âThis partnership with Infoway is very important for us because it will benefit the medical specialists who use our EMR solution and, more importantly, it will benefit how do i get kamagra the patients they care for,â said Anatoly Langer, MD, MSc, FRCPC, FACC, President of Aware MD. ÂThe days of hand written and faxed prescriptions are in the past, and PrescribeIT® is a step forward for all parties involved â physicians, pharmacists and patients.ââWe are excited to work with Aware MD to make PrescribeIT® available to the specialists across Ontario who use the Cerebrum⢠EMR solution,â said Jamie Bruce, Executive Vice President, Infoway.
ÂBy eliminating the how do i get kamagra use of paper and faxed prescriptions, PrescribeIT® makes prescribing safer, more secure, easier and more convenient, resulting in better health outcomes for Canadians.âAbout Aware MDAware MD Inc. Is a Canadian company located in Toronto that has been in business since 2003. Cerebrum⢠is a proprietary workflow solution developed by how do i get kamagra Aware MD Inc. For specialists how do i get kamagra to manage busy multi-diagnostic practices. It is a secure, intuitive and modular software program that can be customized to clinical needs.
It represents the most comprehensive workflow solution available today for how do i get kamagra specialists. Visit www.awaremd.com.About Canada Health InfowayInfoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we help deliver better quality and access to care and more efficient delivery of health services for patients and clinicians how do i get kamagra. Infoway is an independent, not-for-profit organization funded by the federal government. Visit www.infoway-inforoute.ca.About PrescribeIT®Canada how do i get kamagra Health Infoway is working with Health Canada, the provinces and territories, and industry stakeholders to develop, operate and maintain the national e-prescribing service known as PrescribeIT®.
PrescribeIT® will serve all Canadians, pharmacies and prescribers and provide safer and more effective medication how do i get kamagra management by enabling prescribers to transmit a prescription electronically between a prescriberâs electronic medical record (EMR) and the pharmacy management system (PMS) of a patientâs pharmacy of choice. PrescribeIT® will protect Canadiansâ personal health information from being sold or used for commercial activities. Visit www.PrescribeIT.ca.-30-Media Inquiries Karen SchmidtDirector, Corporate/Internal CommunicationsCanada Health Infoway(416) 886-4967 Email UsFollow @InfowayInquiries about PrescribeIT®September 24, 2020 (TORONTO) â Canada Health Infoway (Infoway) and CloudMD how do i get kamagra are pleased to announce that cheap generic viagra co uk kamagra tablets they have reached an agreement to advance e-prescribing in Canada. PrescribeIT® is Infowayâs national e-prescribing service that enables prescribers and pharmacists to electronically create, receive, renew and cancel prescriptions, while improving overall patient care through secure clinician messaging.Under the agreement, CloudMD will integrate its Juno electronic medical record (EMR) with PrescribeITâs solution infrastructure. CloudMD is aiming to have the technical work completed how do i get kamagra in early 2021.
Once complete, physicians and nurse practitioners who offer virtual consultations with patients will be able to send prescriptions electronically from their EMR to the patientâs pharmacy of choice, and pharmacies will be able to request prescription renewals electronically from the patientâs prescriber.âWe are excited to partner with Infoway because we believe a national, modern e-prescribing service will engender greater patient trust and confidence in prescriptions,â said Essam Hamza, MD, Chief Executive Officer of CloudMD. ÂThe enhanced security offered by PrescribeIT® will be beneficial to health providers and patients who use CloudMDâs services.âCloudMD provides virtual medical care to a combined network of 376 clinics, more than 3,000 licensed practitioners and almost three million patients through its technology components.âWe look forward how do i get kamagra to working with CloudMD to make PrescribeIT® more widely available across the country,â said Jamie Bruce, Executive Vice President, Infoway. ÂPrescribeIT® makes prescribing safer, more secure, easier and more convenient by eliminating how do i get kamagra the use of paper and faxed prescriptions, resulting in better health outcomes for Canadians.âAbout CloudMDCloudMD (TSXV. DOC, OTC. DOCRF) is digitizing the delivery of healthcare by providing patients access to how do i get kamagra all points of their care from their phone, tablet or desktop computer.
The Company offers SAAS based health technology solutions to medical clinics across Canada and has developed proprietary technology that delivers quality healthcare through the combination of connected primary care clinics, telemedicine and artificial intelligence (AI). CloudMD currently provides service to a how do i get kamagra combined ecosystem of 376 clinics, more than 3,000 licensed practitioners and almost three million patient charts across its servers. Visit cloudmd.ca.About Canada Health InfowayInfoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we how do i get kamagra help deliver better quality and access to care and more efficient delivery of health services for patients and clinicians. Infoway is an independent, not-for-profit organization funded by how do i get kamagra the federal government.
Visit www.infoway-inforoute.ca.About PrescribeIT®Canada Health Infoway is working with Health Canada, the provinces and territories, and industry stakeholders to develop, operate and maintain the national e-prescribing service known as PrescribeIT®. PrescribeIT® will serve all Canadians, how do i get kamagra pharmacies and prescribers and provide safer and more effective medication management by enabling prescribers to transmit a prescription electronically between a prescriberâs electronic medical record (EMR) and the pharmacy management system (PMS) of a patientâs pharmacy of choice. PrescribeIT® will protect Canadiansâ personal health information from being sold or used for commercial activities. Visit www.PrescribeIT.ca.-30-Media Inquiries Karen SchmidtDirector, Corporate/Internal CommunicationsCanada Health Infoway(416) 886-4967 Email UsFollow @InfowayJulia BeckerVice President, Investor RelationsCloudMDThis email address is being protected from spambots how do i get kamagra. You need JavaScript enabled to view it.Inquiries about PrescribeIT®.